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Abstract 
Lysosomal phospholipase A2 (LPLA2) and lecithin:cholesterol acyltransferase 
(LCAT) belong to a structurally uncharacterized family of lipid metabolizing enzymes 
responsible for lung surfactant catabolism and reverse cholesterol transport, 
respectively. Whereas LPLA2 is predicted to underlie the development of drug-induced 
phospholipidosis, somatic mutations in LCAT cause familial LCAT deficiency (FLD). 
Herein are described multiple high resolution crystal structures of human LPLA2 and a 
low resolution structure of LCAT that confirms its close structural relationship to LPLA2. 
Insertions in the α/β hydrolase core of LPLA2 form domains with unique folds that are 
responsible for membrane interaction and binding the acyl chains and head groups of 
phospholipid substrates. The wide opening of the LPLA2 active site faces the 
membrane for an easy access to glycerophospholipids and lipophilic alcohols, its 
preferred substrates. Based on these structures, substrate modeling, and the position of 
disease-causing mutations in LCAT, we propose that orientation of the bound 
phospholipid in the active site underlies the specificity of LPLA2 for fatty acids in the sn-
2 vs. sn-1 position, and that preference for length of the acyl chains is dictated by two 
hydrophobic grooves leading away from the catalytic triad of the enzyme. We proposed 
a 2-step mechanism for LPLA2 membrane binding, consisting of a transient LPLA2 
interaction with the membrane via its surface hydrophobic residues. High-affinity 
membrane interaction occurs through the bound substrate and the catalytic 
intermediate. Based on LPLA2 structure we built an LCAT homology model and 
validated it by solving the 8.7 Å structure of LCAT. Then we used this model to map 
known genetic LCAT mutations leading to either fish eye disease (FED) or FLD. We 
determined that most FLD-causing mutations result in either structural defects or 
catalytic impairments. On the other hand, FED mutations mostly cluster on the surface 
of the hydrolase domain and might define a surface for LCAT interactions with 
apolipoprotein A (ApoA)-I, a key component of HDL. The LCAT structure thus paves the 
 xii 
way for rational development of new therapeutics to treat FLD, atherosclerosis, and 
acute coronary syndrome. 
 1 
Chapter 1. Introduction 
1.1 Lipases 
Lipases are enzymes that hydrolyze lipids. Lipases function in eukaryotes and 
prokaryotes to maintain lipid homeostasis, hydrolyze ingested triglycerides and 
catabolize them when energy expenditure requires it. Depending on the substrate type, 
lipases can be further divided into phospholipases, triacylglycerol lipases, 
sphingomyelinases, etc. However, most commonly, the term “lipase” refers to 
triacylglycerol lipases (E.C.3.1.1.3), the enzymes that hydrolyze triacylglycerols to 
diacylglycerols and free fatty acids. Some lipases can also perform transesterification 
reactions when the leaving acyl group is conjugated to an acceptor molecule instead of 
water. Alcohols, thiols, and amines can be used as acceptor molecules (Sandoval, 
2012). Bacterial lipases are the most extensively studied and many of their crystal 
structures have been determined (Arpigny & Jaeger, 1999; Jaeger et al., 1994). 
 
1.1.1 α /β  hydrolase fold 
Most triacylglycerol lipases have an α/β hydrolase fold (Ollis, Cheah, Cygler, & 
Dijkstra, 1992), characterized by a central β-sheet usually consisting of seven parallel 
and one antiparallel β-strand, surrounded by α-helixes on either side (Fig. 1). However, 
some lipase lack the β1 and β2 strands, for example, Pseudomonas aeruginosa lipase 
and Bacillus subtilis lipase (Nardini, Lang, Liebeton, Jaeger, & Dijkstra, 2000; van 
Pouderoyen, Eggert, Jaeger, & Dijkstra, 2001). 
These enzymes contain a Ser/Asp/His catalytic triad with an active site serine 
nucleophile (Nu) located at the tip of a nucleophile elbow, an extremely sharp turn with 
strained backbone geometry between the β5 strand and the αC helix. Because of the 
tight geometry, glycines at position Nu-2 and Nu+2, are necessary to avoid steric 
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clashes, generating the lipase motif GxSxG, where “x” can be any amino acid. The 
catalytic triad Asp is commonly found in a loop following β7, and the His in a loop after 
β8. Some of the helixes connecting β-strands can be absent. In addition, various 
insertions in the loops between the C-termini of β-strands and the N-termini of α-helixes 
often constitute additional domains and active site lid elements. 
The oxyanion hole is formed by backbone amides of two amino acids: one in the 
position Nu+1 and the other from an adjacent loop region. In many lipases, the second 
oxyanion-forming residue adopts an optimal position only upon substrate binding when 
the lipase assumes an active conformation (Nardini & Dijkstra, 1999). 
 
 
Figure 1. The canonical α/β hydrolase fold. (a) Topology diagram of a typical α/β 
fold. Green circles depict the catalytic triad residues. (b) The α/β hydrolase fold of a 
lipase from S. exfoliates (PDB 1JFR). Catalytic triad residues are shown as sticks. 
The backbone is colored in rainbow from blue (N-) to red (C-terminus). 
 3 
 
1.1.2 Catalytic cycle 
The catalytic triad of lipases is functionally similar to that of trypsin, despite the 
lack of structural similarity (Arpigny & Jaeger, 1999), and the reaction mechanism is 
very similar between the two enzymes. First, when the substrate binds, the oxygen of 
the carbonyl group positions in the oxyanion hole (Fig. 2a). Then, the catalytic triad 
charge-relay system creates an activated oxygen atom on the nucleophile serine 
hydroxyl group, which attacks the carbonyl carbon on the substrate.  This creates a 
transient tetrahedral intermediate, stabilized by interactions between the backbone 
amides of the oxyanion hole and the negatively charged oxygen atom on the carbonyl 
group of the scissile ester bond (Fig. 2b). The leaving group is then protonated by the 
His of the catalytic triad that had previously taken the H+ from the Nu, leaving the 
catalytic intermediate attached to Nu (acyl enzyme, Fig. 2c). The His residue then 
activates an incoming water molecule, and the resulting OH- group attacks the carbonyl 
group of the acyl enzyme, resulting in the formation of a second tetrahedral 
intermediate. The proton is returned from the His to Ser triggering the release of the 
 
Figure 2. Reaction mechanism of the Ser/His/Asp catalytic triad.  
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product and the completion of the catalytic cycle (Fig. 2d).  
Fluorophosphonate inhibitors covalently and nonspecifically inhibit many α/β 
hydrolase enzymes. The release of hydrofluoric acid traps the enzymes at the acyl 
enzyme step of their catalytic cycle. Such inhibitors were successfully used to solve 
lipase structures in their active conformation (Egloff, Marguet, Buono, & Verger, 1995; 
Roussel et al., 2002). 
 
1.1.3 Interfacial activation and lids 
All lipases work at the water-lipid interface, and many of them are activated by 
lipid surfaces in a phenomenon known as “interfacial activation”. In the absence of such 
activation, the enzyme activity follows the typical Michaelis-Menten dependence on the 
substrate concentration. However, for many lipases a dramatic increase in activity 
occurs when the substrate is presented in the form of micelles or liposomes (Jaeger et 
al., 1994). 
Such behavior is usually attributed to the presence of a mobile “lid”, an element 
that closes off and blocks the active site in the absence of lipids. Upon interaction with a 
lipid interface, the lid is displaced, uncovering the active site, which ultimately leads to 
substrate binding and turnover. Dislocation of the lid also often leads to the exposure of 
large hydrophobic surfaces that increase the enzyme interaction with lipid substrates 
and the membrane itself. 
Lids are formed by elements inserted into the loops of the α/β hydrolase domain 
and can be very different in their size and structure. As such, the mobile lid of 
Pseudomonas aeruginosa lipase is formed from three helixes (α4-α6) and that of 
Candida rugosa has a single mobile helix (Grochulski et al., 1994; Nardini et al., 2000). 
Non mobile elements, which cover the active site of Pseudomonas aeruginosa and 
human gastric lipase, were called the “cap” domain (Canaan, Roussel, Verger, & 
Cambillau, 1999; Nardini et al., 2000). Mutations within the cap domain dramatically 
reduced the activity of human gastric lipase, indicating its importance in substrate 
binding (Miled et al., 2003).  
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Interfacial activation of some lipases also includes a conformational change, 
which is required to bring the catalytic triad and the oxyanion hole into the proper 
alignment for catalysis (Schrag et al., 1997; van Tilbeurgh et al., 1993). Not all lipases 
have lids. Such enzymes also lack the interfacial activation and are constitutively active 
(Martinez et al., 1994; van Pouderoyen et al., 2001). 
 
1.1.4 Phospholipase A2 enzymes 
The phospholipases A2 (PLA2) are a group of enzymes, unrelated in their 
structures and catalytic mechanisms, grouped together on the basis of their common 
reaction of fatty acid hydrolysis from the sn-2 position of phospholipids (Schaloske & 
Dennis, 2006). This group includes small secreted PLA2s, cytosolic PLA2 (cPLA2), 
Ca2+-independent PLA2 (iPLA2), platelet activating factor acetyl hydrolases (PAF-AH), 
lysosomal phospholipase A2 (LPLA2) and adipose specific phospholipase A2 (Dennis, 
Cao, Hsu, Magrioti, & Kokotos, 2011).  
Only cPLA2, iPLA2, PAF-AH and LPLA2 have an α/β hydrolase fold. The 
catalytic mechanism between the groups is also different, with only PAF-AH and LPLA2 
employing the Ser/His/Asp catalytic triad. Similar to bacterial lipases, cPLA2 has a cap 
domain with a lid, located at the top of the active site that blocks access to 
phospholipids. cPLA2 also has a C2 domain and its membrane binding is regulated by 
Ca2+ ions and phosphatidylinositol 4,5-bisphosphate (PIP2). Once at the membrane, 
phospholipid binding triggers the opening of the lid (Dennis et al., 2011). The model of a 
catalytic domain of iPLA2, built based on the crystal structure for cPLA2, suggests an 
absence of any cap domain or lid element. Membrane interaction for iPLA2 likely occurs 
via membrane penetration by a region of the catalytic domain. PAF-AH membrane 
binding occurs via surface-exposed hydrophobic α-helixes. LPLA2 is the only member 
of the group XV phospholipase and little is known about its membrane binding and its 
activation mechanism. 
 
 6 
1.2 LPLA2, a unique group XV phospholipase A2 
1.2.1 LPLA2 discovery  
When incubating N-acetylsphingosine (NAS) with Madin-Darby canine kidney 
(MDCK) cells homogenate, an unknown polar product was found and later identified as 
1-O-acyl-NAS. The homogenate enzymatic activity had a pH maximum of 4.2 and high 
affinity for NAS with Km of 9.4 µM. In contrast to cPLA2 and Coenzyme A (CoA)-
independent transacylases, the unknown enzyme did not utilize free fatty acids or CoA-
fatty acids, but instead transferred fatty acids from glycerophospholipids, such as 1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) (Abe, Shayman, & Radin, 1996). The 
enzyme was later purified from bovine brain and characterized. It exhibited both 
acyltransferase and phospholipase A2 activity, was localized to the lysosomal fraction, 
and had an acidic pH optimum (pH 4.5). It was also Ca2+, Mg2+ and ATP independent, 
and was insensitive to dithiothreitol (DTT) and bromoenol lactone (a cytosolic Ca2+-
independent phospholipase A2 inhibitor) (Abe & Shayman, 1998). Gene sequencing 
and cloning was performed by two independent groups and the enzyme was named 
LCAT-like lysophospholipase (LLPL) (Taniyama et al., 1999) or LPLA2 (Hiraoka, Abe, & 
Shayman, 2002). However, it was discovered that lysophospholipase activity is 
negligible compare to the enzyme acyltransferase or phospholipase activities (Hiraoka 
et al., 2002). 
 
1.2.2 LPLA2 primary and secondary structure and N-glycosylation 
LPLA2 shares 49% sequence identity with lecithin:cholesterol acyltransferase 
(LCAT). Both genes are located on chromosome16q22.1 and are spatially close. LPLA2 
mRNA encodes a 1.3 kb product corresponding to protein 412 amino acids in length. 
Signal sequence predictions suggested a signal peptide cleavage site between amino 
acids 33 and 34 in human LPLA2, leaving a mature protein of 379 amino acids.  
LPLA2 sequence similarity to LCAT suggests it has an α/β hydrolase fold, 
predicted for LCAT by threading algorithms (Peelman et al., 1998). LPLA2 and LCAT 
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have no closely related homologs with a known structure. The LPLA2 primary sequence 
predicted a lipase motif AxSxG located in a sharp turn between a β-strand and an α-
helix (Fig. 3), similar to that of Bacillus subtilis lipase but different from the GxSxG motif 
common to other lipases and LCAT (Ollis et al., 1992). Mutation of the Ala163 in the 
lipase motif to the corresponding Gly found in LCAT results in LPLA2 that retains only 
10% activity of the wild type enzyme. LCAT and LPLA2 sequence alignment identified 
Ser165, Asp327 and His359 as LPLA2 catalytic triad residues. Alanine substitutions at 
any of these positions completely eliminated LPLA2 activity (Hiraoka, Abe, & Shayman, 
2005).  
Human LPLA2 has four cysteines. Cys32 and Cys56 form a disulfide bridge that 
sets apart a so-called “lid” thought to be important in interfacial activation and 
 
Figure 3. Sequence comparison of mature human LCAT and LPLA2. Missense 
mutations in LCAT resulting in disease are highlighted blue for FLD, yellow for FED, 
and green for both (substitution dependent). Catalytic triad residues are marked with 
an asterisk. Cysteine residues that participate in disulfide bonds are highlighted in 
black. Cyan boxes indicate the positions of free LCAT cysteins. The † indicates the 
position in LCAT that when mutated from an acidic residue allows the enzyme to 
accept acyl chains greater than 18 carbons in the sn-2 position. The “lid” proposed to 
cover the active site is bracketed by a disulfide bond and is indicated by a purple line 
above the sequences. Red arrows and orange lines below the sequences indicate 
the predicted positions of secondary structure elements by PSIPRED. Strands and 
helixes are labeled according to Peelman et al. (Peelman et al., 1998). 
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membrane binding. Although DTT does not affect LPLA2 activity, mutations of Cys32 or 
Cys56 completely inactivate the enzyme. The remaining Cys297 and Cys338 remain 
free and are able to interact with organomercury agarose columns (Hiraoka et al., 
2005).  
Asn66, Asn240, Asn256 and Asn365 were found in motifs that match that of the 
consensus for N-linked glycosylation (NxS/T) (F. Schwarz & Aebi, 2011). 
Polysaccharide addition was confirmed via binding to Concavalin A columns. 
Endoglycosidase F1 (endo F1) treatment of LPLA2 expressed in COS-7 cells removes 
N-linked glycosylation and shifts the enzymes apparent molecular weight from 50 kDa 
to 42 kDa as expected from the amino acid sequence (Hiraoka et al., 2002). LPLA2 
glycosylation is required for protein folding and full catalytic activity (Hiraoka, Okamoto, 
Ohguro, & Abe, 2013; O, Hill, Wang, McLeod, & Pritchard, 1993). Alanine substitutions 
at positions 240, 256 and 365 reduced LPLA2 catalytic activity to 37, 32, and 82%, 
respectively. The N66A substitution resulted in an insoluble and misfolded protein. 
1.2.3 LPLA2 catalytic activity and substrate specificity 
LPLA2 acts both as a phospholipase and an acyltransferase. In the 
phospholipase reaction, LPLA2 hydrolyses glycerophospholipids and then uses water 
as an acceptor for an acyl chain (Fig.4a). When certain lipophilic alcohols such as NAS 
are present, LPLA2 acts as an 
acyltransferase, generating O-
linked acyl alcohols (Fig. 4b). 
Presumably, the acidic 
pH optimum arises from 
LPLA2’s reliance on 
electrostatic interactions for 
liposome binding (Abe & 
Shayman, 1998). Thus, 
hydrolysis of p-
nitrophenylbutyrate (pNPB), a 
soluble LPLA2 substrate, can 
 
Figure 4. LPLA2 reaction schemes. (a) 
Phospholipase reaction. (b) Acyltransferase reaction 
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occur over a wide range of pH (4-8). The LPLA2 pH optimum for liposome-based 
reactions is instead very narrow (4-5), and is the same as its pH dependence for 
liposome binding (Abe & Shayman, 2009). 
Charge plays an important role in LPLA2 catalysis. LPLA2 has a strong 
preference for negatively charged glycerophospholipids as its substrates. Consequently, 
liposomes consisting of negatively charged 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)] (DOPG)/NAS, 1,2-dioleoyl-sn-glycero-3-phosphate/NAS or and 1,2-dioleoyl-
sn-glycero-3-phosphoethanol (DOPEt))/NAS were turned over more efficiently then the 
zwitterionic DOPC/NAS. Incorporation of negatively charged inert sulfatide into 
DOPC/NAS liposomes increased the formation of 1-O-acyl-NAS proportionally to the 
ratio of DOPC/NAS to sulfatide. Sulfatide incorporation into negatively charged 
glycerophospholipid (1,2-dioleoyl-sn-glycero-3-phosphoserine, DOPG/NAS, and 
DOPEt/NAS) liposomes produces an additive effect and results in the most efficient 
LPLA2 substrate, sensitive enough to measure LPLA2 activity in blood plasma (Abe, 
Kelly, & Shayman, 2010). The sulfatide effect is counteracted by high salt 
concentrations, and when > 200 mM NaCl is present LPLA2 activity is reduced to 30%, 
presumably due to the loss of liposome association. 
LPLA2 does not have strict specificity for sn-1 or sn-2 positions of 
glycerophospholipids. Rather, this choice is determined by the nature of the acyl groups 
themselves (Abe, Hiraoka, & Shayman, 2006). When given 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC)/NAS/sulfatide or 1-oleoyl-2-palmitoyl-sn-glycero-3-
phosphocholine (OPPC)/NAS/sulfatide liposomes LPLA2 preferentially transfers the 
oleoyl (C18:1) group rather then palmitoyl (C16:0) group, no matter the position. The 
rate of formation for 1-O-oleoyl-NAS was 2.5 or 5 times higher then that of 1-O-
palmitoyl-NAS in POPC or OPPC-containing liposomes, respectively. Comparison of 1-
stearoyl-2-oleoyl-sn-glycero-3-phosphocholine or 1-oleoyl-2-steraroyl-sn-glycero-3-
phosphocholine-containing liposomes confirmed that LPLA2 prefers to act on 
unsaturated fatty acids, and that 1-O-oleoyl-NAS formation always dominated over 1-O-
stearyl-NAS (C18:0).  The length of acyl groups also affects LPLA2 specificity. When 
given a choice between palmitic group in sn-1 position and oleic or linoleic (C18:2) in 
sn-2, LPLA2 acts on the sn-2 position two times more efficiently than on sn-1. However, 
 10 
if the length of the acyl group in the sn-2 position increases, for example, when using 1-
palmitoyl-2-docosahexanoyl-sn-glycero-3-phosphocholine (PDPC)-containing 
liposomes, LPLA2 preference for sn-2/sn-1 positions is only 1.5. Arachidonic acid in the 
sn-2 position is particularly disfavored with a sn-2/sn-1 ratio of 0.24 for 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (PAPC). 
When primary alcohols are present in the liposomes, LPLA2 acts as an 
acyltransferase (Abe, Hiraoka, & Shayman, 2007b). Investigation of preferred LPLA2 
acceptors identified a common chemotype among them: ethanol derivatives with one 
long aliphatic chain and one short neutral residue, such as a methyl or acyl group in the 
C2 position. Thus, a short chain ceramide NAS, with an acetyl group in C2 position is 
favored over N-octanoylsphingosine or oleoylsphingosine (Abe et al., 1996). Acylation 
always occurs at the primary alcohol group. Other acceptors include glycerol derivatives 
complying with the common acceptor structure described above. Glycerol itself is a very 
poor acceptor and works only at a concentration of 30%. However, glycerol derivatives, 
such as 1-O-hexadecyl-2-acetyl-sn-glycerol (HAG), are acylated on the remaining 
primary alcohol group at the C3 position with the formation of 1-O-hexadecyl-2-acetyl-3-
oleoyl-sn-glycerol. This reaction is competitive with NAS acylation when both acceptors 
are present at the same time, and HAG inhibited NAS acylation with an IC50 of 25 µM.  
Both NAS and HAG are biologically relevant molecules. NAS can be produced in 
vivo in HL-60 cells by transferring an acetyl group from PAF to sphingosine by CoA-
independent transacetylase (T. Lee, Ou, Shinozaki, & Malone, 1996) and HAG can be 
converted to PAF by DTT-insensitive cholinephosphotransferase(T. C. Lee, Malone, 
Blank, Fitzgerald, & Snyder, 1990).  In addition, LPLA2 can use biologically active 
oleoylethanolamide and anandamide as acceptors, changing their properties, such a 
lipophilicity, via acylation (Abe, Hiraoka, & Shayman, 2007b). 
The acyltransferase reaction is reversible, and LPLA2 can deacylate 1-O-acyl-
NAS when incubated for prolonged periods of time, releasing a fatty acid and NAS that 
can be utilized again in the acyltransferase reaction. LPLA2 deacylase activity might be 
important for regulation of the cellular phospholipid homeostasis by maintaining the 
levels of biosynthetically important lipophilic alcohols. Thus LPLA2 inhibition in MDCK 
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cells in vitro leads to accumulation of nonpolar lipids (Abe, Hiraoka, & Shayman, 
2007b). 
Although acyltransferase activity itself is not unique to LPLA2, its use of primary 
alcohols as acceptors is. Other known human enzymes possessing acyltransferases 
activity use sterols (LCAT (Szedlacsek et al., 1995)) or lysophospholipids (cPLA2 
(Reynolds, Hughes, Louis, Kramer, & Dennis, 1993)). This unique feature allows for a 
convenient assay for measuring LPLA2 activity in complex systems such as blood 
plasma. Only plasma from mice expressing LPLA2 was able to catalyze the formation of 
1-O-acyl-NAS when incubated with DOPC/sulfatide/NAS (Abe et al., 2010). 
1.2.4 LPLA2 tissue distribution and physiological role 
The tissue distribution of LPLA2 was investigated in rats using the highly 
sensitive and LPLA2-specific acyltransferase reaction, and the highest level of LPLA2 
activity was found in rat alveolar macrophages (AM) (Abe et al., 2004a). LPLA2 activity 
was 40-fold higher in AM than other tissues, including monocytes and peritoneal 
macrophages. It was, in fact, suggested that LPLA2 could serve as a marker for 
terminally differentiated AM. Consistent with increased LPLA2 activity, LPLA2 mRNA 
and protein levels were also significantly elevated in AM compared to other tissues. The 
major function of AM is degradation of pulmonary surfactant, the major component of 
which is dipalmitoylphosphatidylcholine (DPPC) (Agassandian & Mallampalli, 2013). In 
vitro analysis confirmed that LPLA2 hydrolyses DPPC in both the sn-1 and sn-2 
positions (Abe et al., 2004a). 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) deficient mice 
(GM-CSF-/-) exhibit pathologic accumulation of lung surfactant due to a defect in 
saturated phospholipid catabolism (Dranoff, Crawford, Sadelain, & Ream, 1994; 
Ikegami et al., 1996). This defect resembles pulmonary alveolar proteinosis (PAP), a 
rare human disease characterized by accumulation of lipid material in alveoli. GM-CSF-/- 
mice have reduced LPLA2 activity and protein levels (Abe et al., 2008) that correlates 
with reduced LPLA2 mRNA levels in human PAP patients (Malur et al., 2012). 
PAP treatment with rituximab, an antibody to CD20, a B-lymphocyte specific 
antigen, increased levels of GM-CSF via reduction of its autoantibody and consequent 
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increase in lipid transporter ABCG1 and the transcription factor peroxisome proliferator-
activated receptor gamma (PPARγ) (Malur et al., 2012). Rituximab also restores LPLA2 
to the levels of the control group. 
Although there appears to be a link between GM-CSF, PPARγ and LPLA2, the 
exact mechanism of signaling is unknown. It was shown that LPLA2 expression could 
be induced by trans-retinoic acid via retinoid X receptor (RXR) (Abe, Poucher, Hiraoka, 
& Shayman, 2004b). RXR in turn can form heterotrimers with PPARγ, however, no 
involvement of PPARγ was found in LPLA2 gene activation by retinoic acid in THP-1 
cells. 
In response to phagocytic stimuli, AM can secrete LPLA2 into extracellular fluids 
where it can participate in extracellular lipid catabolism (Abe et al., 2008). Catabolytes, 
such as lysophosphatidic acid or arachidonic acid, can serve as G protein-coupled 
receptor ligands or proinflammatory molecule precursors, respectively (Ricciotti & 
FitzGerald, 2011; van Meeteren & Moolenaar, 2007).  
1.2.5 The LPLA2-/- mouse and phospholipidosis 
To elucidate systemic LPLA2 role in lipid metabolism, Hiraoka et al. created a 
LPLA2-/- mouse (Hiraoka et al., 2006). The absence of LPLA2 protein was confirmed by 
the Western blot and by lack of NAS-transacylase activity.  Alveolar and peritoneal 
macrophages from LPLA2-/- mouse showed marked accumulation (2.5-fold and 40%, 
respectively) of phospholipids compared to mice expressing LPLA2, primarily resulting 
from increased levels of phosphatidylcholine and phosphatidylethanolamine. Further 
examination revealed that phospholipid accumulation was due to impaired 
phospholipase A2 activity in these tissues. Taken together these data indicate that 
LPLA2 is a major enzyme responsible for phospholipid catabolism in alveolar 
macrophages and, to a lesser extent, in peritoneal macrophages. Histological 
examination of lung tissues from LPLA2-/- mouse revealed an increase in number and 
size of AM and mononuclear cell infiltrate in airways and blood vessels, an inflammation 
hallmark. Analysis of alveolar and peritoneal macrophages by electron microscopy 
showed an accumulation of multilamellular inclusion bodies, a hallmark of cellular 
phospholipidosis. 
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As described above, LPLA2 relies on electrostatic charge for interaction with 
membranes and the presence of substances that weaken the interaction, such as high 
salt, or pH shifts, results in LPLA2 inhibition. Cationic amphiphilic drugs (CADs) are 
lipophilic molecules that insert into the membrane and become ionized at acidic pH. 
When entering the acidic lysosomal environment their head groups become positively 
charged, effectively trapping them in this compartment. CAD incorporation into 
lysosomal membranes thereby change its charge distribution and can potentially affect 
enzymes working at that interface (Reasor & Kacew, 2001). Administration of certain 
CADs, such as the antiarrhythmic amiodarone, can thus have serious side effects such 
as pulmonary toxicity due to phospholipid accumulation (Heath, Costa-Jussà, Jacobs, & 
Jacobson, 1985). Another CAD, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol (PDMP), is known to cause phospholipidosis in Chinese hamster ovary (CHO) 
cells (Rosenwald & Pagano, 1994). 
MDCK cells treated with amiodarone or PDMP resulted in ~2-fold increase of 
phospholipids, primarily PC and phosphatidylethanolamine (PE), similarly to the 
phenotype observed in AM of LPLA2-/- mouse (Abe, Hiraoka, & Shayman, 2007a). 
Electron micrographs of Madin-Darby canine kidney (MDCK) cells treated with these 
drugs showed accumulation of multilamellular bodies resembling inclusion bodies from 
LPLA2-/-  AM and peritoneal macrophages. Direct evidence that amiodarone and PDMP 
inhibit LPLA2 comes from in vitro assays on DOPC/NAS/sulfatide liposomes, wherein 
they inhibit the NAS-acyltransferase reaction with IC50 of 15 and 40 µM, respectively. 
Such inhibition presumably results from impaired LPLA2 binding to lipid bilayers, 
because amiodarone was shown to inhibit LPLA2 co-sedimentation with DOPC/sulfatide 
liposomes (Abe & Shayman, 2009).  
Phospholipid accumulation in AM of LPLA2-/- mouse can be reversed in vitro by 
introducing catalytically active recombinant LPLA2 to the cultured cells. LPLA2 reuptake 
occurs by carbohydrate recognition via mannose-6-phospate receptors. This results in 
cellular phospholipid profiles becoming similar to wild type. Such an approach can be 
potentially used in enzyme-replacement therapy for cationic drug induced 
phospholipidosis (Abe et al., 2008). 
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1.2.6 LPLA2 in immune response 
Mycobacterium tuberculosis is carried human to human through aerosol 
transmission. It takes residency in lungs and causes tuberculosis, a severe and often 
fatal infectious disease with more then eight million new cases reported annually. The 
first stage of tuberculosis infection is bacterial uptake by resident AM.  They provide the 
initial platform for bacterial replication but also serve to initiate a local immune response 
in lung parenchyma (Korbel, Schneider, & Schaible, 2008). 
Comparing lungs from mycobacterium infected wild type and LPLA2-/- mice 
revealed that bacterial growth and survival is favored in the knockout mice, presumably 
due to an impaired immune response (B. E. Schneider et al., 2014). As such, histology 
of its lung tissues revealed a reduced number of immune cells. Bacteria count in 
spleens was diminished in the LPLA2-/- mice compared to the control group. Further 
analysis revealed that absence of LPLA2 diminishes recruitment and activation of 
cytotoxic CD8+ and antigen specific CD4+ T cells. This could be the result of either 
insufficient macrophage activation in lung tissues or impaired macrophage recruitment 
due to defective chemokine production during the infection. This data, together with 
excessive LPLA2 expression levels in alveolar macrophages, indicate that LPLA2 plays 
an important role in protective host immunity for aerosol transmitted agents, and 
tuberculosis, in particular. 
A novel role for LPLA2 in autoimmunity was recently described (Paduraru et al., 
2013). LPLA2-/- mice have a reduced number of invariant natural killer T cells resulting 
not from their impaired development, but from deficient antigen presentation by CD1d 
molecules. Although the exact nature of CD1d lipid antigens is not clear, some reports 
indicated that lysophospholipids, products of a phospholipase A2 reaction, are 
associated with CD1d molecules. However, it is currently unknown if lysophospholipids 
are true antigens or if they have a regulatory role in loading actual antigens on CD1d. 
LPLA2 deletion seems to alter the lipids presented by CD1d molecules. 
Older LPLA2 -/- mice are characterized by an excessive presence of auto 
antibodies, such as anti-nuclear and anti-dsDNA antibodies. In addition they develop 
lymphoid hypertrophy and have high immunoglobulin levels. Such condition resembles 
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systemic lupus erythrematosis, an autoimmune decease characterized by antibody 
development to the organisms own antigens (Murphy, Lisnevskaia, & Isenberg, 2013). 
Thus, LPLA2 importance in immunity is supported by multiple studies, although the 
exact mechanism remains unknown. 
1.2.7 LPLA2 role in atherosclerosis 
LPLA2 was found to be protective in atherosclerosis. When ApoE-/- mice, a 
laboratory model for atherosclerosis, were crossed with LPLA2-/- mice, Taniyama et al. 
observed an increased number of atherogenic lesions, suggesting that LPLA2 presence 
might mitigate the development of atherosclerosis by reducing apoptosis in 
macrophages and consequently reducing thrombogenicity of the atherogenic plaque 
(Mallat & Tedgui, 2001). As such, LPLA2 was proposed to a have dual role in apoptosis 
prevention. First, it might be responsible for oxidized LDL degradation in lysosomes. In 
LPLA2-/- mice accumulation of oxidized LDL leads to their encapsulation by 
macrophages, followed by foam cell formation during the first stages of plaque 
development (Maiolino et al., 2013). Second, LPLA2 reduces ceramide levels by 
converting it into inert 1-O- acylceramides. Ceramide levels are known to increase in 
lipoproteins found in atherogenic lesions and may in itself enhance the atherogenicity of 
lipoprotein particles (Auge, Nègre-Salvayre, Salvayre, & Levade, 2000). 
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1.3 LCAT, a cholesterol esterifying enzyme 
1.3.1 Primary sequence and structure predictions 
As mentioned above, mature LCAT is 49% identical in sequence to LPLA2. 
Sequence similarity is equal throughout the sequence with notable exceptions at the N- 
and C- termini and the signal sequence which contains 24 amino acids and is unrelated 
to that of LPLA2 (C. Y. Yang, Manoogian, Pao, & Lee, 1987).  
Yang et al. first recognized the resemblance of the LCAT active site to those of 
serine esterases, such as trypsin, carboxylesterase and pancreatic lipase, and identified 
S181 as a part of GxSxG consensus (C. Y. Yang et al., 1987).  S181 was later 
confirmed as an active site serine via site-directed mutagenesis (Francone & Fielding, 
1991b; Qu, Fan, Blanco-Vaca, & Pownall, 1994). 
Using threading algorithms, Peelman et al. predicted that LCAT has an α/β 
hydrolase fold consisting of a central parallel 7–stranded β-sheet (Peelman et al., 1998). 
To be consistent with the nomenclature for other α/β hydrolases (Ollis et al., 1992), the 
first LCAT β-strand was designated as β2. Such arrangement places S181 in the 
position of the nucleophile elbow at a sharp turn between β-strand 5 and helix 5-6 (Fig. 
3). The same authors also identified and confirmed by mutagenesis residues composing 
the catalytic triad, H377 and D345, and what they believed was the oxyanion hole, 
composed of L182 and F103. 
Peelman et al. also proposed an existence of a “lid”, a domain similar to the one 
found in many lipases where it serves to close off the hydrophobic active site when the 
enzyme is not engaged in catalysis. Many such lids are set apart by a disulfide bridge. 
LCAT has six cysteine residues with positions 50-74 and 313-356 forming disulfide 
linkages (C. Y. Yang et al., 1987). LCAT C50-C74 region was proposed to be 
homologous to the C60-C97 lid domain of Candida rugosa lipase. Consistent with this, 
its deletion completely abolished LCAT activity (Peelman et al., 1998). 
Recently, another LCAT model was created using the Robetta web server (Sensi 
et al., 2014). Authors of this manuscript came to similar conclusions as Peelman et al., 
regarding the overall α/β fold, catalytic triad, oxyanion hole and lid positions. In addition 
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they presented the first model of LCAT elements outside of the hydrolase domain 
including the whole LCAT sequence into prediction. The extreme N-terminus of LCAT 
was built ab initio. Overall, this model predicts a very open cholesterol-binding site 
crowned by the lid, with all additional elements composing a single domain with a β-
sheet at its center. As will be shown later (Chapter 4.6), this model is incorrect, 
reflecting difficulties in modeling structures of proteins with low homology to unknown 
structures. 
Both of these models place C31 and C184 in the vicinity of the active site. Their 
role in LCAT activity was probed through modification and mutagenesis. Jauhiainen et 
al. used monofunctional (dithionitrobenzoic acid and p-aminophenylarsendichloride) and 
bifunctional reagents (p-bromoacetylaminophenylarsenonide) to probe these cysteines 
(Jauhiainen & Dolphin, 1986; Jauhiainen, Stevenson, & Dolphin, 1988). The bifunctional 
reagent completely inhibited LCAT phospholipase and acyltransferace activity and 
suggested a vicinal position of the two cysteines at a distance of 3.5 – 3.6 Å between 
their sulfur atoms. Interestingly, both dithionitrobenzoic acid and p-
aminophenylarsendichloride modifications inhibited acyltransferase, but not 
phospholipase activity, suggesting that either C31 or C184 or both are located at the 
acceptor-binding site. Cysteine substitution with a small amino acid glycine, C31G or 
C184G, had no effect on LCAT activity, confirming that cysteine residues themselves do 
not participate in catalysis but are rather located in the close proximity to the active site 
(Francone & Fielding, 1991a). C31 substitution to hydrophobic amino acids (C31Y, 
C31F and C31I) enhanced LCAT transacylase activity at least 50% compared to the 
wild type enzyme, indicating that hydrophobic interaction might participate in acceptor 
binding. Recombinant LCAT protein, mutated to enhance its catalytic activity, was 
patented as a therapeutic for the treatment of atherosclerosis, thrombosis, coronary 
heart disease and for the decrease or prevention of cholesterol accumulation (Boone, 
Meininger, Schwarz, & Shan, 2012). 
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1.3.2 LCAT N- and O-linked glycosylation 
Plasma LCAT is heavily modified with N- and O-linked glycosylation that can 
constitute up to 25% of its mass. Glycosylation directly or indirectly (through effects on 
protein secretion and/or stability) affects LCAT activity. As a result, under glycosylated 
LCAT expressed in baculovirus-infected Sf21 cells had reduced activity compared to 
plasma LCAT or recombinant protein expressed in CHO cells (Miller, Wang, Sorci-
Thomas, Anderson, & Parks, 1996). The majority of polysaccharide modifications of 
plasma LCAT are N-linked, and LCAT treatment with peptide N-glycosidase F 
(PNGaseF), which removes all N-linked sugars under denaturing conditions, reduces 
the apparent LCAT molecular weight (MW) to the expected 46kDa (Collet & Fielding, 
1991). However, mass spectrometry also identified O-linked glycosylation at T407 and 
S409 consisting of sialylated galactose β1➝3N-acetylgalactosamine structures. LCAT 
O-linked glycosylation was not extensively studied and its role is unknown (Schindler, 
Settineri, Collet, Fielding, & Burlingame, 1995). However, C-terminally truncated LCAT 
(LCAT1-401) retains full acyltransferase activity, suggesting that O-glycosylation does not 
play an important role in an enzyme function (Francone, Evangelista, & Fielding, 1996; 
Y. P. Lee et al., 1997).  
N-linked glycosylation occurs at N20, N84, N272 and N384 (Fig. 3). Electrospray 
ionization mass spectrometry identified polysaccharide composition at positions N20, 
N84 and N272 to consist of triantennary and at N384 of biantennary complex structures 
(Schindler et al., 1995). LCAT is a secreted protein and N-glycosylation is important for 
its expression. Thus, tunicamycin, an inhibitor of the first step of N-glycosylation in the 
endoplasmic reticulum (Elbein, 1987), completely abolishes active LCAT expression in 
CHO cells. Similarly, inhibition of the first stages of N-glycan processing in the 
endoplasmic reticulum, such as with castanospermine, deoxynojirimycin or 
methyldeoxynojirimycin, also resulted in the secretion of inactive LCAT. However, 
inhibitors of the later stages in N-glycan processing, such as by swainsonine or 
deoxymannojirimycin, had no effect on LCAT secretion and activity (Collet & Fielding, 
1991).  
Multiple groups have tried to distinguish the roles of individual N-glycosylation 
sites via site-directed mutagenesis (Francone, Evangelista, & Fielding, 1993; Kosman & 
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Jonas, 2001; O et al., 1993; Qu, Fan, Blanco-Vaca, & Pownall, 1993). The greatest 
impact on LCAT expression and acyltransferase activity is caused by substitutions at 
N84 and N272. The effect of mutation at N272 varied from a lack of expression for 
N272T (Qu et al., 1993) to reduced acyltransferase activity for N272Q (1% and 14% of 
wild type for acyltransferase and phospholipase activities, respectively (Francone et al., 
1993)). A mutation of N84 also coincided with significant loss of LCAT transacylase 
activity from 8% relative to wild type for N84Q and to 26% for N84T (Francone et al., 
1993; Qu et al., 1993). Disruption of N-linked glycosylation at positions N20 or N384 
had very little effect on LCAT activity or protein expression levels. 
The potential function of N-glycosylation in maintenance of LCAT stability was 
investigated using the N84Q and N384Q mutants (Kosman & Jonas, 2001). In 
agreement with previous data, the N384Q mutant had activity similar to the wild type 
LCAT, but it gradually declined over the course of a 7-month incubation at 4 °C whereas 
wild type activity remained essentially the same. Circular dichroism (CD) and 8-Anilino-
1-naphthalenesulfonic acid (ANS) fluorescence studies confirmed that N384Q 
denatures at a faster rate then wild type LCAT. N84Q CD spectra and ANS 
fluorescence curves closely resemble those of N384Q after denaturation and suggest 
that substitution at position N84 increases the rate of LCAT denaturation even further. 
Thus, LCAT glycosylation probably prevents denaturation and aggregation of this 
enzyme in plasma. 
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1.3.3 HDL composition 
Like LPLA2, LCAT can either hydrolyze phospholipids or perform a 
transesterification reaction, transferring a fatty acid from the sn-2 position of 
glycerophospholipids to cholesterol (Fig.5). 
In vivo this reaction primarily takes place 
on high density lipoprotein (HDL) particles 
and low density lipoprotein (LDL) particles. 
Based on their electrophoretic mobility on 
agarose gels, HDL and LDL particles are 
also called α- and β- lipoproteins, 
respectively. LDL particles are metabolic 
products of very low-density lipoproteins 
and mainly serve to remove excess 
triglycerides from peripheral tissues. In 
contrast, HDL particles remove excess 
cholesterol in the form of cholesterol esters 
and deliver it to either sterogenic tissues 
for utilization in metabolic processes or to the liver for degradation.  
HDLs and LDLs have very different lipid and protein content (Table 1). The most 
abundant protein in HDL particles is ApoA-I, followed by ApoA-II and minor apo-proteins 
(ApoE and ApoCs) (Jonas & Phillips, 2008). The only protein component of LDL 
particles is ApoB100 (Segrest, Jones, De Loof, & Dashti, 2001).The majority of lipids on 
HDL and LDL particles are cholesterol, cholesterol esters, glycerol- and phospholipids. 
Phospholipids are primarily represented by phosphatidylcholine (PC), sphingomyelin, 
and minor amounts of lysoPC. Lipid acyl group composition is represented by palmitic 
(16:0), stearic (18:0), oleic (18:1), linoleic (18:2) and arachidonic (20:4) fatty acids 
(Jonas & Phillips, 2008). 
 
 
Figure 5. LCAT acyltransferase reaction 
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1.3.4 LCAT association with lipoprotein particles 
The rates of LCAT hydrolase and acyltransferase reactions on lipoprotein 
interfaces strongly depend on the kinetics of LCAT binding to HDLs and LDLs, which in 
turn depends on interaction with lipids and apo-proteins. Based on the discrepancies 
between LCAT enzymatic activity HDL-binding constants, it is generally accepted that 
LCAT catalytic reaction on lipoprotein particles can be divided in two steps. The first 
step is lipid binding, which is independent of apoproteins (Bolin & Jonas, 1994). The 
second step is LCAT activation by lipoproteins.  
LCAT catalysis on the lipoprotein interface is affected by pH and salt 
concentrations.  Highest LCAT activity is observed at 0.15M NaCl, the physiological salt 
concentration in human plasma. At that salt concentration, the pH optimum of the 
enzyme is 8.5 (Jonas, Daehler, & Wilson, 1986). Salt concentration has no effect on 
LCAT hydrolysis of the soluble substrates  
Lipid composition can also affect LCAT binding. As such, sphingomyelin inhibits 
LCAT activity in a concentration-dependent manner by impairing its binding to the lipid 
interface (Bolin & Jonas, 1996). On the other hand, the presence of 14% cholesterol in 
1-palmitoyl-2-oleoyl PC (POPC) vesicles increases LCAT binding affinity 4-fold (from 
2.2 µM Kd to 530 nM), as 
measured using radiolabeled 
LCAT and ApoA-I (Miller & 
Parks, 1997). 
Overall, LCAT is only 
transiently associated with 
lipoprotein particles and falls 
off after each catalytic cycle. 
As such, the dissociation rate 
constant for HDLs and LCAT 
is identical to the LCAT 
catalytic rate constant (0.05 s-
1), suggesting that LCAT falls 
Table 1. Composition of HDL and LDL particles.  
 
LDL HDL 
size, Å 250 120-70 
total protein, (% weight) 20-25 52-60 
ApoA-I, (% protein weight) -  70 
ApoA-II, (% protein weight) - 20 
ApoB-I, (% protein weight) 100 - 
ApoCs and ApoE, (% protein 
weight) - 10 
total lipid,  (% weight) 75-80 40-48 
phospholipids, (% lipid weight) 28-30 42-51 
cholesterol, (% lipid weight) 10-12 6-8 
cholesterol ester, (% lipid weight) 47-51 24-45 
glycerolipids, (% lipid weight) 7-11 6-7 
Adapted from (Jonas & Phillips, 2008) and  
(Segrest et al., 2001). 
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off HDL particles after each catalytic cycle (Adimoolam, Jin, Grabbe, Shieh, & Jonas, 
1998). 
 
1.3.5 Substrate selectivity. Donor preference 
As in LPLA2, LCAT glycerophospholipids selectivity is influenced by their head 
groups and length and saturation of the acyl groups. LCAT prefers neutral phospholipid 
head groups, such as ethanolamine and choline. Intermediate LCAT activity can also be 
observed with phosphatidylglycerol. Phosphatidylserine and phosphatidic acid are the 
poorest LCAT substrates (Pownall, Pao, & Massey, 1985).  
Human LCAT can hydrolyze a wide range of diacyl-phospholipids as a part of 
reconstituted HDL particles, from C12:0 to C22:6, with arachidonic acid being a notable 
exception. The highest rate of cholesterol transesterification was observed with linoleic 
(18:2), erucic (22:1) and docosohexaenoic (22:6) fatty acids (Grove & Pownall, 1991). 
Comparing more physiological phospholipids, containing palmitic acid in the sn-1 
position and various unsaturated fatty acids in sn-2, human LCAT had the highest rate 
of cholesterol transesterification with 1-palmitoyl-2-oleoyl PC (POPC) followed by 1-
palmitoyl-2-linoleoyl PC (PLPC) with the lowest rate corresponding to the longest and 
most unsaturated phospholipids PAPC, 1-palmitoyl-2-eicosa-pentaenoyl PC and PDPC 
(Parks, Thuren, & Schmitt, 1992).  The nature of the double bonds in unsaturated 
glycerophospholipids, and, hence, membrane fluidity, also has an effect on LCAT 
activity. Thus, LCAT transacylase activity on trans 18:1 or 18:2 fatty acid in sn-2 position 
is at least five times lower then for equivalent cis- acyl groups (Parks, Huggins, Gebre, 
& Burleson, 2000). 
Interestingly, LCAT from other mammalian species have different preferences for 
fatty acid content. Notably, rat, dog and sheep LCATs can readily utilize diarachidonyl 
PC (Grove & Pownall, 1991). Parallel comparison of human and rat LCAT specificity for 
POPC or PAPC incorporated in recombinant HDL particles revealed that rat LCAT could 
utilize both phospholipids equally (PAPC/POPC ratio is 0.97) whereas human LCAT 
prefers POPC (PAPC/POPC ratio is 0.33). Alteration of human LCAT specificity can be 
achieved by a single substitution, E149A, (Fig. 3) converting it into the rat enzyme (J. 
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Wang, Gebre, Anderson, & Parks, 1997; Zhao, Gebre, & Parks, 2004; Zhao, Wang, 
Gebre, Chisholm, & Parks, 2003). It was proposed that Glu149 is located in the vicinity 
of the active site and the charge of Glu149 of the human enzyme hinders the binding of 
long-chain fatty acids. 
LCAT has a clear positional specificity for acyl groups in sn-2 position. Thus, in 
the presence of symmetric phospholipids, LCAT transfers acyl groups from sn-2 
positions with almost 100% selectivity, independent of the chain length or saturation 
state (from palmityc to arachidonic acids) (Liu, Subramanian, & Subbaiah, 1998). 
However, human LCAT has considerable sn-1 activity if the sn-2 position is occupied by 
an extra long polyunsaturated fatty acid, such as arachidonic or docosohexaenoic acids. 
In such cases the nature of fatty acid in sn-1 position is the primary determinant of 
LCAT positional specificity. For example, if arachidonic acid is present in the sn-2 
position and palmitic in sn-1, almost half of synthesized cholesterol ester will be 
palmitoyl-cholesterol. This sn-1/sn-2 ratio decreases with increased length of fatty acid 
in the sn-1 position (Liu et al., 1998; Subbaiah, Liu, & Paltauf, 1994). In agreement with 
disparate specificity of rat LCAT, its positional specificity is not altered dramatically by 
the presence of long unsaturated fatty acids in the sn-2 position (Liu et al., 1998). 
In addition to glycerophospholipids, LCAT can use platelet activation factor (PAF) 
as a substrate. This reaction does not require lipoprotein cofactors and results in the 
formation of lysoPAF and acetate in the hydrolase reaction or, if lysoPC is present, of 
lysoPAF and the 1-acyl derivative of PAF. These reactions lead to PAF inactivation and, 
as such, LCAT might play a role in PAF metabolism. However, this reaction is about ten 
times slower than the rate of the forward reaction of cholesterol esterification and about 
200 times slower than PAF hydrolysis by PAF-acetylhydrolase (Liu & Subbaiah, 1994). 
In addition to PAF, LCAT is able to hydrolyze and inactivate other oxidized polar 
phospholipids (Goyal, Wang, Liu, & Subbaiah, 1997). Because LDL oxidation is an early 
event during atherosclerosis, LCAT might be involved in preventing an accumulation of 
oxidized lipids in LDL particles in plasma, thereby maintaining healthy lipid metabolism 
in humans (Itabe et al., 1999).  
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1.3.6 Substrate and acceptor selectivity 
In the presence of suitable acceptors, LCAT transfers an acyl group from a 
phospholipid donor to an alcohol, forming an ester bond. The most efficient LCAT 
acceptors are sterols, however it can also esterify primary aliphatic alcohols. 
Esterification of aliphatic alcohols strongly depends on their chain length. The best 
aliphatic alcohol acceptor is 1-O-hexadecanol and increasing or decreasing its acyl 
chain progressively reduces its esterification by LCAT (Kitabatake, Piran, Kamio, Doi, & 
Nishida, 1979). 
Cholesterol is the most abundant sterol in plasma of healthy humans and is a 
good acceptor for the acyl group in transesterification reaction. However, other sterols 
can also serve as acceptors in transacylase LCAT reaction. The general rules for 
sterols to be efficient acceptors are: 1) β-configuration of hydroxyl group at C3 and 2) 
the A and B rings have to be in either planar or trans configuration. Sterols that do not 
satisfy these requirements, such as coprostanol, epicholesterol, epicholestanol, or 
epiandrosterol have at least a 100-fold lower esterification rate then cholesterol.  
Modifications of the aliphatic tail of the cholesterol do not have a profound effect on  
LCAT activity.  The addition of a double bond at C22 and extra acetyl group at C24 
reduces the sitosterol esterification rate by about 50%. Complete removal of the 
aliphatic side chain leads to a slight increase in androsterol esterification rate (Piran & 
Nishida, 1979). The same rules for LCAT acceptors were shown to apply in vivo when 
LCAT was assayed on sterols derived from plasma of Smith–Lemli–Opitz syndrome and 
sitosterolemia patients, which have increased amounts of plant sterols in their plasma 
(Lin, Steiner, Merkens, Pappu, & Connor, 2010). Oxisterols are also good LCAT 
acceptors. 27-hydroxycholesterol, for example, has the same esterification rate as 
cholesterol (Szedlacsek et al., 1995). 
LCAT is able to at least partially reverse the cholesterol esterification reaction. 
When LCAT was incubated with proteoliposomes containing doubly labeled 
[3H]cholesterol-[14C]oleate, the formation of cholesterol-[14C]oleate and [3H]cholesterol-
linoleate was observed but not [14C]PC, indicating that the reversal is limited to the acyl 
transfer step of the enzymatic reaction (Sorci-Thomas, Babiak, & Rudel, 1990). 
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LCAT also possesses lysolecithin acyltransferase activity. In this 
transesterification reaction, LCAT uses an extra lysoPC molecule as an acceptor for the 
acyl group. Such reactions can occur on LDL particles which have significant lysoPC 
content ( Jonas & Phillips, 2008; Liu & Subbaiah, 1993; Subbaiah & Bagdade, 1978; 
Subbaiah, Albers, Chen, & Bagdade, 1980). 
1.3.7 LCAT activation by apoproteins 
Very early in LCAT studies it was found that LCAT activity on lipoproteins is 
significantly enhanced in the presence of protein cofactor derived from HDL particles (C. 
J. Fielding, Shore, & Fielding, 1972). It was shown that ApoA-I, ApoA-II ApoE and 
ApoCs increase the Vmax of LCAT esterification reactions on HDLs or LDLs when using 
either cholesterol or lysoPC as acceptors, with ApoA-I having the greatest effect (Jonas, 
Sweeny, & Herbert, 1984; Liu & Subbaiah, 1993; Zorich, Jonas, & Pownall, 1985). 
Activation happens at or before the acyl-intermediate formation step and, as such, can 
affect both esterase or transacylase reactions of LCAT (Yokoyama, Fukushima, 
Kupferberg, Kézdy, & Kaiser, 1980). However, apolipoproteins do not affect the rate of 
hydrolysis for soluble substrates of LCAT (Bonelli & Jonas, 1989) suggesting that 
activation is only important for LCAT action on lipid surfaces. 
Multiple laboratories investigated the region of ApoA-I responsible for LCAT 
activation. Deletion of helixes 6 and 7 (amino acids 143-164, 165-186 or the whole 
region 148-186) from ApoA-I almost completely abolished LCAT activation (Minnich et 
al., 1992; Sorci-Thomas, Kearns, & Lee, 1993). However, deletion of other regions in 
the ApoA-I N- and C-terminal region (amino acids 66-87, 99-120, 187-208, 209-219 and 
212-233) also significantly reduced LCAT activation (Minnich et al., 1992; Sorci-Thomas 
et al., 1993). In addition, there are known mutations in humans in the central ApoA-I 
region that are characterized by reduced ability to activate LCAT (E110K, V156E and 
H162Q) (Hoang, Huang, Sasaki, & Sviridov, 2003). 
LCAT regions responsible for enzyme activation by apoproteins is not well 
defined. However, natural LCAT mutations causing fish eye disease (described later), 
such as T123I, N131D and N391S are thought to interfere with either HDL binding or 
the ApoA-I activation mechanism (Vanloo et al., 2000). Inaccessibility of amino acids 
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121-136 to antibody binding upon LCAT interaction with lipoproteins further suggests 
that the α3-4 helix, defined by Peelman et al. (Peelman et al., 1998), is in close 
proximity to the potential LCAT-ApoA-I binding interface (Murray et al., 2001). 
Interestingly, an amphiphilic docosapetide unrelated to apoproteins in its 
sequence is also able to activate LCAT, albeit to a lesser extent then the ApoA-I protein 
(18% cholesterol esterification rate and 50% fatty acid release) (Yokoyama et al., 1980), 
suggesting that amphipathic helixes have the ability to activate LCAT. 
 
1.3.8 LCAT and reverse cholesterol transport 
LCAT binds to nascent discoidal pre-β HDL particles, generated from lipid-free or 
lipid-poor ApoA-I lipidation via ABCA1 transporter (Fig.6). Only one LCAT molecule can 
bind per HDL particle (Bolin & Jonas, 1994). LCAT activation by ApoA-I results in 
cholesterol esterification and formation of very hydrophobic cholesterol esters that 
migrate into the core of HDL particles. This results in the formation of mature spherical 
α-HDLs which are distinguished by increased amount of cholesterol esters compared to 
discoidal pre-β HDL (Kunnen & Van Eck, 2012). 
Very early after LCAT discovery, Glomset et al. recognized its role in reverse 
cholesterol transport (RCT) (Glomset, Janssen, Kennedy, & Dobbins, 1966). 
Conversion of cholesterol to cholesterol-esters on HDL particles creates a gradient of 
cholesterol between lipoproteins and cell membranes and allows for cholesterol efflux 
from peripheral tissues and macrophages, preventing cholesterol transport back to 
extrahepatic tissues. Cholesterol transport itself could proceed either by passive 
diffusion or via active export through the ABCG1 transporter. α-HDLs then deliver the 
excess cholesterol to hepatocytes in the liver to be ultimately secreted in the form of bile 
salts (Kunnen & Van Eck, 2012).  
Currently, however, the role of LCAT in reverse cholesterol transport is being 
questioned. The controversy arose due to new insights into the mechanism of 
cholesterol efflux from the cells, which, as opposed to previous data, is an ATP-
dependent process happening through multiple transporters and thus should not 
depend significantly on the gradient of 
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cholesterol. In addition, patients with LCAT deficiency accumulate cholesterol only in 
certain tissues, such as corneas, kidneys, and erythrocytes.  
Many studies using transgenic animals have been done to determine the effect of 
LCAT gene deletion or overexpression on the cholesterol levels in an attempt to find a 
link between LCAT activity and atherosclerosis and cardiovascular disease. 
Unfortunately, the results of these studies are inconsistent with each other partially due 
to the use of different model systems (reviewed in (Kunnen & Van Eck, 2012)). Thus, 
the role of LCAT in atherosclerosis remains to be determined. However, even now, 
LCAT biotherapeutics are being patented for the treatment of “atherosclerosis, 
thrombosis, coronary heart disease and for decreasing or prevention of accumulation of 
cholesterol” in humans (Boone, Meininger, Schwarz, & Shan, 2012). 
 
 
Figure 6. LCAT role in HDL maturation. 
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1.3.9 LCAT familial diseases 
There are more then 90 different LCAT mutations described in humans that 
cause rare familial autosomal recessive diseases - familial LCAT deficiency (FLD) and 
fish eye disease (FED) (www.lcat.it).  Usually, only homozygous mutations result in 
clinical phenotypes with heterozygotes retaining half-maximal HDL-associated 
cholesterol levels (Calabresi, Simonelli, Gomaraschi, & Franceschini, 2012). FLD 
patients completely lack LCAT activity in plasma on HDL and LDL lipoproteins (defined 
as α- and β- activity) (Fig. 7). Biochemical manifestation results in very low HDL- and 
LDL- associated cholesterol, low plasma cholesterol-ester levels, and highly variable 
levels of triglycerides. The FLD phenotype includes corneal opacification, proteinuria, 
and anemia. Morbidity is typically due to renal failure. 
The FED phenotype is less severe compared to FLD and manifests only in 
corneal opacification due to cholesterol accumulation in corneas. In FED, LCAT activity 
on LDL particles is 
preserved (β-activity) 
while HDL-associated 
LCAT activity (α-
activity) is significantly 
reduced. Consistent 
with the uncertain role 
of LCAT in 
atherosclerosis, FED 
and FLD patients do 
not seem to have an 
increased risk of 
cardiovascular disease 
(Calabresi et al., 2012). 
 
Figure 7. LCAT mutations causing FLD or FED 
phenotype differently affect LCAT association with 
different lipoproteins. 
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 Chapter 2. LPLA2 and LCAT expression and 
deglycosylation. 
2.1 Attempts to deglycosylate LPLA2 produced in HEK293T cells 
The primary goal of this project was to crystallize and determine the structure of 
LPLA2 using the x-ray diffraction method. The Shayman laboratory had already 
purchased significant quantities of recombinant human LPLA2 containing a His6 tag on 
its C-terminus from Proteos, Inc. The protein was expressed in HEK 293T cells and was 
purified in a glycosylated form. Although we were able to obtain crystals of LPLA2 
(Chapter 3), they exhibited poor diffraction with severe anisotropy. We hypothesized 
that the poor diffraction quality was due to the presence of N-linked glycosylation, which 
occurs at four Asn residues (N66, N240, N256 andN365) and is very heterogeneous, 
constituting up to a quarter of LPLA2 apparent molecular weight (Hiraoka et al., 2002). 
Thus, given large amount of available material, we attempted to remove sugar moieties 
posttranslationally using endo- and exoglycosidases. 
2.1.1 LPLA2 deglycosylation with endoglycosidases  
Endoglycosidases cleave the inner part of carbohydrates releasing intact sugar 
moieties. Several types of endoglycosidases exist, exhibiting different specificities for 
the polysaccharide moieties they cleave and, also, for their cleavage site within the 
polysaccharide chain. 
 30 
2.1.1.1 Cleavage with peptide-N-glycosidase F (PNGase F) 
PNGase F cleaves between the innermost N-acetylglucosamine residue and Asn 
of the protein releasing the intact glycan chain and reducing the Asn to Asp. PNGase F 
has a very broad specificity for the polysaccharide chain and thus can cleave complex, 
hybrid, high- and low mannose chains (Maley, Trimble, Tarentino, & Plummer, 1989) 
(Fig. 8). PNGase F is more effective after sodium dodecyl sulfate (SDS)-denaturation of 
target proteins, presumably, due to increased accessibility of its cleavage site. 
We digested LPLA2 with PNGase F (5:1) molar ratio in 20 mM HEPES pH 7.5, 
150 mM NaCl at 20 °C and took samples at the indicated time points (Fig. 9). The assay 
was performed using both native and SDS-denatured LPLA2 (5 min incubation at 80 °C 
 
Figure 8. Types of carbohydrates and their susceptibility to endo- and 
exoglycosidases used in this study. 
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with 0.5% SDS and 
40 mM DTT). SDS-
denatured LPLA2 is 
completely digested 
by PNGase F after 
15 min of incubation 
judged by complete 
disappearance of 
the fuzzy LPLA2 
band at 50 kDa 
(Fig, 9, 0’) and an appearance of a well-defined band at 40 kDa (estimated molecular 
weight of glycan-free LPLA2 is 43 kDa). However, in the absence of SDS, only a small 
band of deglycosylated LPLA2 appears after 15’ incubation.  This band most likely 
represents the PNGase digest of the small fraction of denatured LPLA2 present in the 
sample, as it does not appear to increase after 1 h. Thus, it appears that PNGase F is 
able to deglycosylate only denatured LPLA2.  
 Next, we tried to determine if partial unfolding with detergents could promote 
PNGase digestion of LPLA2 (Fig. 10a). LPLA2 was incubated with PNGase F (3:1 
molar ratio) in 50 mM HEPES pH 7.5 for 3 or 24 h in the presence of either 1% β-OG or 
10 mM CHAPS (concentration of both detergents is just below their critical micelle 
concentration). Similar to the PNGase F digest of native protein, only a small fraction of 
LPLA2 is shifted to lower MW on the gel. The percentage of digested LPLA2 seemed to 
be independent of the detergent presence of and did not seem to increase after 24 h of 
incubation, in particular, in the samples incubated at 20 °C. Such behavior is, again, 
consistent with PNGase F acting on spontaneously denatured LPLA2.  
 
Figure 9. PNGase F deglycosylates LPLA2 efficiently only 
after SDS-denaturation. d/g LPLA2, deglycosylated LPLA2. 
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As PNGase F is stable in up to 5 M urea (Maley et al., 1989) we also tried 
various urea concentrations for partial LPLA2 unfolding (Fig. 10b). LPLA2, PNGase F 
and 0.67 or 1.3 M urea were incubated for 30’ in conditions indicated for Fig. 10. 
Similarly to PNGase deglycosylation in the presence of other mild detergents, β-
octylglucoside (β-OG) and CHAPS, no polysaccharide removal occurred. An increase of 
urea concentration to 4M also did not have any effect (data not shown).  
In summary, any attempts to remove polysaccharide moieties from LPLA2 with 
PNGase F prove to be unsuccessful without complete SDS-denaturation the protein.  
 
 
 
Figure 10. LPLA2 deglycosylation by PNGase F in the presence of mild detergents. 
(a) PNGase F digest in the presence of β-OG and CHAPS. (b) PNGase digest in 
the presence of urea. 
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2.1.1.2 Cleavage with endoglycosidases Hf and F1 
Endoglycosidases H (endo H) and F1 (endo F1) both hydrolyze polypeptide-
attached carbohydrates between two inner-core N-acetyl-glucosamines (GlcNAc) 
leaving one GlcNAc attached to the asparagine residue of the protein. The enzymes 
have similar specificities for the carbohydrate moieties: both endo F1 and endo H 
cleave high-mannose or hybrid structures. Endo F1 could also cleave sulfated high 
mannose structures and endo H is very efficient in releasing polysaccharides with 
fucose attached to the core GlcNAc (Sigma-Aldrich Co. LLC, 2008; Trimble & Tarentino, 
1991). Both enzymes have been successfully used for deglycosylation of native proteins 
for subsequent crystallization (V. T. Chang et al., 2007; Grueninger-Leitch, D'Arcy, 
D'Arcy, & Chène, 1996). Endo Hf is an MBP-fusion of endo H and maintains the same 
properties and specificity. 
First, we attempted to remove LPLA2 carbohydrates using endo Hf. We mixed 10 
µg of native or SDS-denatured LPLA2 with 1000 U of endo Hf (NEB) in two different 
buffers – pH 7.5 (20 mM HEPES, 150 mM NaCl) or pH 5.25 (100 mM Na citrate; pH 
optimum for endo Hf (Sigma-Aldrich Co. LLC, 2008)) and incubated at 20 °C for 1 h 
(Fig. 11a) and for 24 h (data not shown). We observed no polysaccharide removal in 
any of the endo Hf containing samples, including the ones containing denatured LPLA2. 
To confirm that the enzyme was catalytically active in our reaction we have tested its 
activity using RNase B (Sigma) as a substrate (Fig. 11b). We tested both pH 6.0 and 
4.5 (buffered by 100 mM Na citrate), and after 1 h at 37 °C, we observed complete 
deglycosylation indicated by a shift in apparent molecular weight of RNAse B, proving 
that endo Hf is capable of releasing carbohydrates at conditions tested. Its inability to 
deglycosylate LPLA2 is, therefore, most likely due to the complex structure of LPLA2 
glycans, which are apparently unrecognizable by endo Hf. 
Previously, LPLA2 partially purified from COS-7 cells overexpressing LPLA2 was 
shown to be sensitive to endo F1 digest (Hiraoka et al., 2002). Thus, we tested our 
available LPLA2 preparation from HEK 293T cells for its susceptibility to endo F1. We 
expressed and purified endo F1 (plasmid was a kind gift from Dr. Warren, University of 
British Columbia) according to the previously described protocol (Kwan, Boraston, 
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McLean, Kilburn, & Warren, 2005). The enzyme was enzymatically active under the 
same conditions used for endo Hf treatment, judged by its ability to remove 
polysaccharides from RNase B (Fig. 11b). We next tested its ability to deglycosylate 
LPLA2 under the same conditions.  We used 1:3 molar ratio of endo F1 to LPLA2 and 
the same buffers described for the RNase B digest. However, we observed no shift in 
the apparent molecular weight of LPLA2 at all temperatures tested (4, 20 and 37 °C), 
both pH (4.5 and 6.0) or after prolong incubation for 15 h. Increasing the enzyme 
concentration 5-fold (Fig. 11c, lane “5x endo F1”) or SDS denaturation (Fig. 11c, lane 1) 
also did not promote LPLA2 deglycosylation. 
Discrepancy with previously published data regarding LPLA2 sensitivity to endo 
F1 is probably due to the source of the protein. Hiraoka et al. used cell lysates for 
deglycosylation experiments, which likely did not contain mature LPLA2 since it was not 
yet fully processed for protein secretion (Hiraoka et al., 2002). On the other hand, 
LPLA2 produced by Proteos, Inc. was purified in a secreted form from the cell media 
and thus most likely contained complex polysaccharide moieties resistant to endo Hf 
and endo F1. 
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Figure 11. LPLA2 deglycosylation with endo Hf and endo F1 glycosidases. 
(a) LPLA2 deglycosylation with endo Hf. (b) RNase B deglycosylation with 
endo Hf and endo F1. (c) LPLA2 deglycosylation with endo F1. 
 36 
2.1.2 LPLA2 deglycosylation with exoglycosidases 
Next we attempted to use exoglycosidases in hopes to reduce glycosylation 
heterogeneity in native conditions. Exoglycosidases release terminal monosaccharides 
from the non-reducing end of polysaccharides. The specificity of exoglycosidases is 
usually determined by the type of monosaccharide they release and the type of the 
carbohydrate link.  
First, we attempted to remove terminal sialic acid residues using sialidase (NEB). 
Sialidase removes sialic acid linked through α2-3, α2-6, and α2-8 bonds 
(www.neb.com). For this we incubated 13 µg of LPLA2 with 50 U of sialidase in 100 mM 
Na citrate pH 6.0 for 3 and 15 h at 4, 20 and 37 °C and looked for the shift in LPLA2 
apparent molecular 
weight on Coomassie 
stained SDS- 
polyacrylamide gel 
electrophoresis 
(PAGE) gel (Fig. 
12a). After 3 h at 4 °C 
we observed a small 
shift and compression 
of the LPLA2 band 
that was most likely 
due to reduced 
heterogeneity of the 
sample upon the 
sialidase treatment. 
Comparing results 
after 3 or 15 h we concluded that reaction was finished after 3 h. As only one sialic acid 
caps each branch of carbohydrates, it is conceivable that the modest shift we observed 
reflected the removal of all LPLA2-bound sialic acid residues.  And, though the sample 
was still highly heterogeneous, as judged by the remaining broadness of the LPLA2 
 
Figure 12. LPLA2 deglycosylation with endo- and exo- 
glycosidases. (a) LPLA2 digest with sialidase. (b) LPLA2 digest 
with a combination of sialidase and endo Hf or endo F1. 
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band after sialidase treatment, we proceeded with crystallization trials (Chapter 3). We 
have also attempted to combine sialidase with endo F1 in hopes that after the release of 
sialic acid from the reducing end of carbohydrates, the high mannose or hybrid 
glycosylation moieties suitable for endo F1 digest will be exposed. We performed the 
reaction in the same conditions as the sialidase digest for either 3 h (data not shown) or 
15 h at 20 and 37 °C (Fig. 12b). We did not observe any additional glycan removal 
when combining sialidase with either endo F1 or endo Hf that could not be attributed to 
the action of sialidase alone. 
Next, we attempted to include more exoglycosidases for sequential saccharide 
removal. We chose to use β1-4-galactosidase and β-N-acetylglucosaminidase (NEB), 
because these enzymes were readily available and because β1-4-galactose and β-N-
acetyl-glucose are common components of complex carbohydrate moieties. For 7 µg of 
LPLA2 we used 36 pmol of endo F1, 25 U of sialidase, 4 U of β1-4-galactosidase and 
2U of  β-N-acetylglucosaminidase. All reactions were performed in 100 mM Na citrate 
buffer pH 6.0 at 20 °C for 5 h (data not shown) or 15 h (Fig. 13). Again, no additional 
shift in LPLA2 mobility was observed compared to the sample containing only LPLA2 
and sialidase. 
Thus, the complex glycosylation moieties of LPLA2 either do not contain β1-4-
galactose and β-N-acetyl-glucose, or, more likely, these residues are blocked by other 
monosaccharides at their reducing end and, thus, are not susceptible for digest with 
their respective exoglycosidases. And, though, there are many more exoglycosidases 
 
Figure 13. LPLA2 digest with various exoglycosidases. 
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available we have decided that without knowing the exact structure of LPLA2 
carbohydrates it would be unwise to try them at random. Thus, we switched to new 
strategies with the goal of expressing LPLA2 with predefined glycan moieties. 
2.2 LPLA2 expression in HEK 293S GnTi- cell line 
To limit the complexity of glycosylation in mammalian expression systems 
several cell lines have been created with various mutations of the enzymes in the 
glycosylation pathways, such as a series of mutant CHO Lec cell lines bearing 
mutations conferring resistance to various lectins (Stanley, 1989). Similarly, Reeves et 
al. isolated a mutant HEK 293S cell line that was resistant to ricin (Reeves, Callewaert, 
Contreras, & Khorana, 2002), which lacked N-acetylglucosaminyltransferase I (GnTI) 
activity and was designated GnTI-. Loss of GnTI activity resulted in N-linked glycans 
that have a common mannose5GlcNAc2 structure (Fig. 8, “high mannose”) that is very 
sensitive to endo H (V. T. Chang et al., 2007). 
First we attempted to establish a protocol for transient LPLA2 expression in 
adherent monolayers of HEK 293S GnTi- cells grown in DMEM high-glucose media, 
supplemented with 10% fetal bovine serum (FBS), 1 mM pyruvate, 2 mM L-glutamine, 
100 U/ml penicillin, and 100 µg/ml streptomycin. The original plasmid, containing 
LPLA2, was provided by Proteos, Inc. and the encoded codon-optimized full-length 
LPLA2 gene, including its signal sequence, followed by a 6xHis tag and tobacco etch 
virus (TEV) protease cleavage site, followed by sequence corresponding to mature 
LPLA2 in PCEP4 plasmid. For convenience (PCEP4 plasmid is very large – 11 kb) the 
construct was subcloned into the smaller pcDNA4 vector (pcDNA4-LPLA2). When 
optimizing the expression protocol we varied cell confluence at the time of transfection, 
type and ratio of DNA transfection reagent and expression time. Aliquots of conditioned 
media were pulled from the Petri dishes at indicated time intervals (Fig. 14). At the end 
of the experiment (72 h) cells were trypsinized and cell lysates were also analyzed.  
Fig. 14 shows a representative Western blot stained with anti-His antibodies 
(Sigma) from the best expression experiment. The gel mobility of LPLA2 expressed in 
HEK 293S GnTI- cells is intermediate between that of LPLA2 from HEK 293T cells 
containing complex carbohydrates and LPLA2 after PNGase deglycosylation under 
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denaturing conditions. This, together with the relative compactness of LPLA2 band, is 
consistent with a homogenous high-mannose type of LPLA2 glycosylation. 
DNA:polyethylenimine (PEI) ratio has the most effect on the level of LPLA2 
expression. In addition to the 1:1 and 1:2 ratios shown on Fig. 14, we have also tested 
1:3 and 1:4 ratios (data not shown), however the 1:2 ratio produced the highest LPLA2 
expression levels. We also tested the commercially available lipophilic transfection 
reagent TransIT (Myrus), however, the results were indistinguishable from PEI (data not 
shown). Cell confluency at the time of transfection did not significantly affect the levels 
of expression and could be raised up to 80% without drastic effects (Fig. 14 and data 
not shown). Protein expression can be detected as early as 48 h and LPLA2 levels 
continued to rise up to 96 h post transfection (data not shown). We also compared the 
levels of LPLA2 secreted into the media to LPLA2 retained inside the cells (Fig. 14 “72 h 
cells” vs. “72 h media”). Although the lysed cells had many contaminants that cross-
reacted with anti-His antibodies, taking into account the relative volumes of conditioned 
media and cell lysates, we concluded that most of LPLA2 is being secreted. The small 
LPLA2 fraction observed from the “cells” sample most probably reflected the protein 
going through the maturation process inside the endoplasmic reticulum and Golgi 
apparatus.  
 
Figure 14. LPLA2 test expression in adherent HEK293S GnTi- cells. Conditioned cell 
media was collected at indicated time points and analyzed by the Western blot under 
denaturing conditions using anti-His6 antibodies. At the end of the experiment, cells 
were harvested and analyzed. Lane (1), LPLA2 from HEK 293T cells, lane (2), 
LPLA2 from HEK293T cells after PNGase F digest. 
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Next, we performed a test expression and purification of the LPLA2 expressed in 
the HEK 293S GnTI- (GnTI- LPLA2) using the protocol yielding the highest LPLA2 
levels. Cells were transfected using 1:2 DNA:PEI ratio at 80% confluency and the 
conditioned media was harvested 4 d later. Media from cells expressing LPLA2 was 
supplemented with HEPES pH 7.5 to a final concentration of 50 mM and then loaded on 
a 0.3 ml Ni-NTA-column. After washing with 10 ml buffer containing 20mM HEPES pH 
7.5, 300 mM NaCl, and 10 mM imidazole pH 8, LPLA2 was eluted using the same 
buffer containing 200 mM imidazole pH 8. 
The resulting 
sample was visualized on 
a silver-stained SDS-
PAGE gel and Western 
blots with anti-His or anti-
LPLA2 antibodies (Fig. 
15). As can be seen from 
Fig. 15a, the sample of 
LPLA2 after Ni-column 
purification still contained 
many impurities, 
presumably due to the 
high serum content of the 
media (10%). GnTI-LPLA2 
treatment with endo F1 in 
native conditions or 
PNGase F treatment in the 
presence of SDS resulted 
in decrease of its apparent 
molecular weight and gel 
mobility becoming identical 
to that of PNGase F-
treated denatured LPLA2 expressed in HEK 293T cells (Fig. 15c). Band corresponding 
 
Figure 15. Deglycosylation of Ni-NTA purified LPLA2 
produced in HEK293S GnTi- cells. (a) Silver stained 
SDS-PAGE gel. (b) The Western blot with anti-His 
antibodies. (c) The Western blot with anti-LPLA2 
antibodies. 
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to endo F1-treated LPLA2 migrated slightly slower than PNGase F-treated LPLA2 due 
to the presence of four remaining GlcNAc (one at each of the four glycosylation sites) 
resulting in about 1 kDa difference between these LPLA2 species. Thus, LPLA2 
expressed in HEK 293S GnTI- cells and secreted into the media is sensitive endo F1 
treatment. 
HEK 293S GnTI- cells can also be grown in suspension cultures to higher cell 
densities relative to adherent cells and could potentially produce the higher amounts of 
protein needed for crystallographic studies. Therefore, we began optimization of LPLA2 
expression in suspension culture of HEK 293S GnTI- cells. We started by switching cells 
to shaking cultures in FreeStyle media containing 10% FBS. Although the cell growth 
and viability were unaffected, the protein expression levels were significantly lower then 
in corresponding adherent cultures (Fig. 16).  
Concurrently, Proteos, Inc. established a protocol for high-scale expression of 
LPLA2 from suspension HEK 293S GnTI- cells that was successful for purification for up 
to 2 mg of LPLA2 per l of media, which we adopted for all our subsequent LPLA2 
expression and purification experiments. The protocol included gradual cell adaptation 
to the FreeStyle media with lower FBS content (0.5%), lowering DNA:transfection 
reagent ratio to 1:1.5 (this later proved to be not significant) and transfection at higher 
cell densities (1.5x106/ml instead of 0.7 x106/ml we used before). 
Thus our routine protocol for LPLA2 expression and purification from HEK 293S 
GnTI- cells for subsequent crystallization was as follows. HEK293S GnTi- cells were 
grown in suspension in FreeStyle media supplemented with 0.5% FBS. At a cell density 
 
Figure 16. LPLA2 expression in suspension culture of HEK293S GnTi- cells. lane (1) 
shows LPLA2 expressed in adherent culture. Shown here is a Western blot with anti-
LPLA2 antibodies. 
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of 1.5x106/ml cells were transiently 
transfected using a 1:2 molar ratio of 
pcDNA4-LPLA2:PEI and conditioned 
media was harvested 5 d later. Then, 
media was supplemented with 
HEPES pH 7.5 to a final 
concentration of 50 mM and then 
loaded on a 3 ml Ni-NTA-column. 
After washing with 100 ml buffer 
containing 20 mM HEPES pH 7.5, 
300 mM NaCl, and 10 mM imidazole 
pH 8, LPLA2 was eluted using the same buffer containing 200 mM imidazole pH 8 (Fig. 
17, lane 1). TEV (5% of total protein) and a 1:10 molar ratio of endoF1:LPLA2 were 
added to the eluate and the protein was dialyzed overnight at 4 °C against 20 mM 
HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT (Fig. 17, lane 2). The protein was then 
passed through a second Ni-column to remove the cleaved His tag and undigested 
protein. The flow-through was further dialyzed against 20 mM HEPES pH 7.5 and 150 
mM NaCl and then concentrated to 13 mg/ml (Fig. 17, lane 3). Yields were about 2 mg/l 
of media of pure and homogeneous sample that was suitable for crystallographic 
experiments (Chapter 3).  
The summary of different LPLA2 glycosylation species with corresponding glycan 
structures is shown on Fig. 18a. All shown LPLA2 glycoforms, with the exception of 
PNGase F-treated denatured LPLA2 have been crystallized (Chapter 3). As mentioned 
in the introduction (Chapter 1) LPLA2 glycosylation is important for its enzymatic activity 
and mutations abolishing N-linked glycosylation led to partial loss of LPLA2 activity 
(Hiraoka et al., 2013). To validate that LPLA2 expressed in HEK293S GnTi- cells and 
deglycosylated with endo F1 (LPLA2GnTI;F1) is functionally indistinguishable from LPLA2 
expressed in HEK 293T cells, we performed comparative biochemical assays. 
First, we compared the enzymatic activities of LPLA2GnTI;F1 and LPLA2 
expressed in HEK 293T cells using both soluble and liposome based substrate (Fig. 
18b and c). LPLA2 can hydrolyze pNPB to p-nitrophenoxide and butyric acid. pNPB 
 
Figure 17. Purification of LPLA2 
expressed in culture of HEK293F GnTi- 
cells. lane 1 – elution after the first Ni 
column, lane 2 – sample after TEV and 
endo F1 digest, lane 3 – final sample after 
the second Ni column. Coomassie stained 
gel from the SDS-PAGE under denaturing 
conditions. 
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(Sigma) was diluted to 10 mM using the reaction buffer (20 mM HEPES pH 7.5, 150 mM 
NaCl) containing 10% DMSO, and the reaction was started by addition of 40 µl 0.1 µM 
LPLA2 to 10 µl of pNPB. Release of the p-nitrophenoxide was monitored by increased 
absorbance at 400 nm on a Spectramax plate reader. Activity of LPLA2 expressed in 
HEK293S GnTi- cells after endo F1 treatment was at least as high as LPLA2 from HEK 
293T cells. 
Next, we compared the acyltransferase activity of the two LPLA2 species. This 
 
Figure 18. Expression, deglycosylation, and covalent modification of LPLA2. (a) 
Coomassie stained gel of various glycosylated forms of LPLA2. The enzyme has 
four N-linked glycosylation sites that proved resistant to deglycosylation when 
expressed in HEK293T cells. Crystal structures were obtained for all but the 
peptide-N-glycosidase F (PNGaseF) treated form. (b) LPLA2 expressed in 
HEK293S GnTi- cells after endoF1 treatment is just as if not more active than wild-
type when evaluated using pNPB as a substrate, indicating that deglycosylation of 
all but the terminal sugar does not greatly affect the structure of the enzyme. (c) 
Acyltransferase activity of endoF1-treated LPLA2 is similar to that of wild-type. 
Error bars in panels B and C represent the standard deviation of three independent 
experiments. Assays were performed by V. Hinkovska-Galcheva. (d) Tm of LPLA2 
expressed in various cell lines before and after reaction with MAFP. In panel d, the 
error bar represents the standard deviation of three independent experiments 
performed in triplicate. * p<0.05; ns, not significant. (e) Scheme of LPLA2 reaction 
with MAFP 
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activity relies on the ability of LPLA2 to bind liposomes and lipid substrates. The 
transacylase activity assay of LPLA2 was performed using a reaction mixture containing 
48 mM Na citrate pH 4.5, 10 µg/ml bovine serum albumin, and liposomes (127 µM 
phospholipid) and LPLA2 in 500 µl of total volume. Liposomes consisting of DOPC-
sulfatide-NAS (3:0.3:1, molar ratio) were prepared as previously described (Abe et al., 
1996). The reaction was initiated by the addition of the enzyme. The reaction mixture 
was incubated for 30 min at 37 ˚C and terminated by adding 3 ml of chloroform-
methanol (2:1) plus 0.3 ml of 0.9% (w/v) NaCl. The mixture was centrifuged for 5 min at 
room temperature. The resulting lower organic layer was transferred into another glass 
tube and dried under a stream of N2 gas. The dried lipid was dissolved in 40 µl of 
chloroform-methanol (2:1) and applied on an HPTLC plate and developed in a solvent 
system consisting of chloroform-acetic acid (90:10, v/v). The plate was than dried and 
soaked in 8% (w/v) CuSO4·5H2O, 6.8% (v/v) H3PO4, 32% (v/v) methanol. The uniformly 
wet plate was briefly dried by a hair dryer and charred for 15 min in a 150 ˚C oven. The 
plate was scanned and the content of the product (1-O-acyl-NAS) was estimated by 
NIH-ImageJ 1.37v.  The activity of LPLA2 from HEK293S GnTi- cells after endo F1 
treatment was slightly lower (about 10%). 
Next, we compared melting temperatures of LPLA2 glycoforms using differential 
scanning fluorimetry method (Fig. 18d). 0.1 mg/ml LPLA2 variant was mixed with 0.1 
mM 1-anilinonaphthalene- 8-sulfonic acid (ANS) in the absence or presence of 100 µM 
methyl arachidonyl fluorophosphonate (MAFP), a covalent LPLA2 inhibitor that upon 
reaction with LPLA2 forms a complex resembling an acyl enzyme step in LPLA2 
catalytic cycle (Fig. 18e), in 20 mM HEPES pH 7.5 and 150 mM NaCl. Samples were 
then heated from 25 to 90 °C at 1 ˚C/min in a ThermoFluor Analyzer (Johnson & 
Johnson). Plate fluorescence was measured in 1 °C intervals after cooling to 25 °C 
using a 475-525 nm emission filter. Tm values were calculated as the inflection point of 
the melting curve using the instrument software. As can be seen from Fig. 18d, the 
difference between apo- and MAFP-bound LPLA2GnTI;F1 and LPLA2 from HEK 293T 
cells was not statistically significant. Thus, we concluded that LPLA2GnTI;F1 biochemically 
is very similar to fully glycosylated LPLA2 from HEK 293T cells. 
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2.3 LCAT expression for crystallographic studies 
2.3.1 LCAT expression in HEK 293T cells 
LCAT is a close homolog of LPLA2 and we speculated that it could be expressed 
using the protocols for LPLA2 expression for HEK 293T and HEK 293S GnTI- cells. 
First, we expressed LCAT in HEK 293F cells using transient transfection. The DNA 
construct contained LCAT sequence optimized for expression in mammalian systems 
(Invitrogen) encoding full-length human LCAT gene with its signal sequence followed by 
a C-terminal His tag subcloned into the pcDNA4 vector. All cell culture protocols were 
the same as for the suspension-grown HEK 293S GnTI- cells for the exception of the 
cell media: HEK 293F cells did not require FBS supplementation of the FreeStyle 
media. LCAT was purified similarly to LPLA2, but the endoF1 and TEV digests were 
omitted as well as the second Ni-column purification step. Yields were about 1.5 mg/l of 
media. 
LCAT expressed in HEK 293F cells had an apparent molecular weight of about 
65 kDa, judged by its mobility on the Coomassie stained SDS-PAGE, and, presumably 
was glycosylated with complex carbohydrates similarly to LPLA2 expressed in HEK 
293T cells (Fig. 19). Furthermore, like LPLA2, LCAT was resistant to the treatment by 
both endo Hf and 
endo F1 
endoglycosidases. 
PNGase F treatment 
of SDS-denatured 
LCAT for 1 h at 20 °C 
resulted in a shift of 
the LCAT band to 
about 45 kDa, an 
expected molecular 
weight of this protein 
based on its protein 
 
Figure 19. Deglycosylation of LCAT expressed in HEK 
293F cells. Coomassie stained gel of purified LCAT from 
HEK 293F cells before and after treatment with various 
endoglycosidases. 
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sequence. Small residual band might correspond to the O-glycosylated LCAT (Schindler 
et al., 1995). Surprising, however, was the ability of PNGase F to act on native protein. 
It has been reported previously that LCAT expressed in CHO was amenable to PNGase 
deglycosylation under native conditions (Chisholm, Gebre, & Parks, 1999), however, its 
similarity to LPLA2 made this observation unanticipated. In addition to being 50% 
identical to LPLA2, three out of four N-linked LCAT glycosylation sites are conserved 
between two proteins, suggesting a similar chemical environment for the protein-
carbohydrate bonds and, thus, similar sensitivity to PNGase F.  
To further investigate this 
phenomenon we used gel-filtration to 
separate deglycosylated LCAT from 
PNGase F. Fig. 20 demonstrates the 
Coomassie-stained SDS-PAGE gel of 
LCAT expressed in HEK 293F cells before 
(Fig. 20 lane 1) and after PNGase F 
treatment in native conditions (Fig. 20 lane 
2). Digested LCAT was applied onto a 
Superdex 200 column equilibrated in the 20 
mM HEPES pH 7.5 150 mM NaCl. The 
chromatogram showed two peaks – one corresponding to PNGase F (apparent 
molecular weight 16 kDa) and one corresponding to LCAT (apparent molecular weight 
65 kDa) (data not shown). One representative fraction of the LCAT peak is shown in 
Fig. 20 lane 3. As can be seen, its gel mobility is identical to that of glycosylated LCAT 
before PNGase treatment.  
The most likely explanation for the observed phenomenon is that PNGase F 
digest of “native” LCAT samples actually occurred during boiling samples in SDS-
containing loading buffer in preparation for the SDS-PAGE when LCAT denaturation 
was happening before PNGase F inactivation. The melting temperature of LPLA2 is 
about 10 ° higher then that of LCAT in ThermoFluor experiments, therefore, heat 
inactivated PNGase F faster then it could denature LPLA2. Thus, unfortunately, similarly 
to LPLA2, we were unable to deglycosylate LCAT produced in HEK 293F cells without 
 
Figure 20. LCAT deglycosylation 
with PNGase F. (Coomassie-
stained SDS-PAGE) 
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prior denaturation of the protein. Nevertheless, we attempted to crystallize this form of 
LCAT, but our crystallization trials thus far yielded no hits.  
Compared to LPLA2, LCAT has additional N- and C-terminal extensions that are 
not predicted to have secondary structures (Fig. 3). The C-terminal extension is 
enriched in prolines and O-linked glycosylation sites (Schindler et al., 1995). The C-
terminus of LCAT is not expected to be important for its catalytic activity (Francone et 
al., 1996; Y. P. Lee et al., 1997). On the other hand, N-terminus has been proposed to 
be involved with LCAT association with HDL and LDL particles (Vickaryous, Teh, 
Stewart, & Dolphin, 2003). 
We have expressed and 
purified C-terminally (LCAT1-397) and 
both N- and C-terminally (LCAT21-397) 
truncated LCAT. LCAT21-397 lacks the 
N- and C-terminal extensions absent 
in LPLA2 (Fig. 3). In addition, it also 
lacks the first N- glycosylation site 
(N20), however, elimination of the 
first glycosylation site should not 
result in significant reduction of the 
LCAT enzymatic activity (O et al., 
1993; Qu et al., 1993).  Both 
constructs have C-terminal 6xHis 
tags and were purified according the 
same protocol as LCATFL. 
Expression levels were comparable 
to those of the full-length protein 
(LCATFL). A representative 
Coomassie stained gel from the 
small scale LCAT purification is 
shown on Fig. 21a. LCAT truncation 
mutants migrate faster on the gel 
 
Figure 21. Activity and melting temperatures of 
different LCAT truncation mutants expressed in 
HEK 293T cells. (a) Coomassie-stained 
denaturing SDS-PAGE of LCATFL, LCAT1-397 
and LCAT21-397 (b) LCATFL, LCAT1-397 and 
LCAT21-397 exhibit no significant difference in 
activity using pNPB as a substrate, (c) Tm 
values of LCAT variants before and after 
reaction with MAFP and IDFP.  
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according to their reduced molecular weight.  
Next we compared the activity of all three LCAT variants using the soluble 
substrate pNPB. A representative experiment is shown on Fig. 21b and 22a. It appears 
that C-terminal deletion had no effect on LCAT ability to hydrolyze pNPB. Deletion of 
the LCAT N-terminus, on the other hand, resulted in increased rate of hydrolysis.  
We have also compared the melting temperatures of all three LCAT truncations 
with and without inhibitors using ThermoFluor assay (Fig. 21c and 22b).  Here we used 
two different fluorphosphonate inhibitors that differ in the length of their acyl chains, 
isopropyl dodec-11-enylfluorophosphonate (IDFP) and MAFP (Fig. 22c). It has been 
reported that human LCAT disfavors phospholipids containing arachidonic acid as its 
substrate due to the presence of a charged amino acid at position 149 (E149) (J. Wang 
et al., 1997; Zhao et al., 2003; 2004). Consistently, LCAT variants do not bind and are 
not stabilized by MAFP in the ThermoFluor assay. On the other hand, the shorter IDFP 
inhibitor stabilized all variants equally by about 6 °C. 
 
 
 
 
 
 
 
 
 
Figure 22. Biochemical properties of LCAT variants. (a) LCATFL and 
LCAT21-397 exhibit no significant difference in activity using pNPB as a 
substrate, indicating that the N and C terminal extensions do not 
contribute to catalytic activity. (b) Tm values of LCAT variants before and 
after reaction with MAFP and IDFP (all experiment were performed in 
triplicates, error bars represent a stand deviation). (c) IDFP and MAFP 
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2.3.2 Creation of stably transfected HEK 293S GnTI- cell lines 
overexpressing LCAT or LPLA2 
Following the same strategy we used for LPLA2, we attempted to transiently 
express LCAT in HEK 293S GnTI- cells in order to get underglycosylated high-mannose 
carbohydrates amenable to endo F1 treatment. We used the same constructs described 
in Section 2.3.1, LCATFL, LCAT1-397 and LCAT21-397. In addition, we tested a longer 
LCAT1-401 truncation that contained the R399A substitution caused FLD (H. Miettinen, 
Gylling, Ulmanen, Miettinen, & Kontula, 1995). All cell culture protocols were the same 
as described for LPLA2 in Section 2.2, and purification identical to that of the fully 
glycosylated LCAT species described in Section 2.3.1.  
Representative Coomassie-stained gel of purified LCAT truncations before and 
after endo F1 treatment is shown on Fig. 23. All LCAT variants appear to be 
heterogeneous, judged by the multiple bands before and after endo F1 digest. Endo F1 
treatment caused the shift in the apparent molecular weight of LCAT constructs due to 
removal of N-linked carbohydrates. However, the heterogeneity of the sample remained 
unaffected. Such heterogeneity might be a result of additional O-glycosylation or 
modifications of N-linked polysaccharides, such as fucosylation, rendering the 
carbohydrates resistant to endo F1. In addition, the yields of all four variants were very 
low, estimated at less than 100 µg/L of media, about 20-fold lower then LPLA2 yields 
from this cell line. 
 
Figure 23. Purified LCAT truncation mutants LCATFL, LCAT1-401, LCAT1-397 and 
LCAT21-397 before and after endo F1 treatment. Coomassie-stained SDS-PAGE. 
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The possible cause of low protein yields could be cellular toxicity of the 
expressed protein, misfolding, protein aggregation, poor secretion, or poor ribosomal 
synthesis. Visual observation did not reveal any loss in cell viability upon LCAT 
expression. However, we also tested the expression of the catalytically inactive S181A 
LCATFL, where the serine of the catalytic triad was substituted to alanine. The 
expression level of this mutant was similar to that of LCATFL.  
To test for potential protein aggregation and misfolding we examined HEK 293S 
GnTI- cells for LCAT accumulation using the Western blot and did not detect significant 
cross reactivity with anti-His antibodies (data not shown). This data argued against 
protein aggregation, however, it did not exclude the possibility that misfolded protein 
was rapidly degraded in cells.  
The signal sequence of secreted proteins could dramatically affect their 
expression level (Stern, Olsen, & Tröße, 2007). To investigate such a possibility, we 
substituted LCAT signal sequence with that of LPLA2. However, no improvement in 
protein expression levels was observed. Thus we concluded that reduced glycosylation 
state of LCAT somehow affected its folding and secretion, possibly, through directing it 
to rapid degradation within the cell.  
Because we were still detecting only small amounts of expressed LCAT, we 
attempted to improve the yields by creating stably transfected HEK 293S GnTI- cell 
lines. In addition to a LCATFL-expressing cell line we also created a LPLA2 expressing 
cell line which later proved to be very useful for the expression of the selenomethionine 
(SeMet)-labeled LPLA2 (Chapter 3). 
We used LPLA2 and LCATFL constructs cloned into PCEP4 and pcDNA4 
plasmids, harboring the resistance to hydromycin and zeocin antibiotics, respectively. 
Plasmids were linearized using SspI restriction endonuclease for pcDNA4 and NruI for 
PCEP4 plasmid. HEK 293S GnTI- cells were grown as adherent monolayers and 
transfected using the previously described protocol for transient expression of LPLA2 
(Section 2.2). On the next day after transfection we began the selection by adding 50 
µg/ml of zeocin (Invitrogen) to cultures transfected with pcDNA4 plasmid and 75 µg/ml 
of hydromycin (Invitrogen) to cultures transfected with PCEP4.  Most cells died over the 
next 5 d, with only a few surviving cells transfected cultured that later gave rise to cell 
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colonies. The Western blot detected protein expression only in pcDNA4-transfected 
cultures and not in the PCEP4 cultures, thus, they were dropped from future trials. After 
cells were recovered (about three weeks after the addition of antibiotic), selection 
pressure was increased to 200 µg/ml 
zeocin in 50 µg/ml steps. Media was 
exchanged every 5 d and cells were 
viable for at least four collections for 
protein purification purposes. 
Estimated yield were about 9 mg/L 
for LPLA2 and 6 mg/L for LCATFL. 
The Coomassie stained gel of 
representative protein samples 
purified using the Ni-resin before or 
after the endo F1 digest are shown 
in Fig. 24.  Both LPLA2 and LCAT 
expressed in their corresponding 
stable cell lines are amenable to 
endo F1 digestion resulting in single 
band for LPLA2 and LCAT. LCAT 
also exhibited some heterogeneity. 
The Western blot stained with anti-
LPLA2 antibodies (Fig. 24b) or anti 
LCAT antibodies (Fig. 24c) confirmed the identity of the expressed protein.  
Next we performed large-scale LCAT expression and purification for 
crystallographic experiments (Fig. 25). As both endo F1 and LCATFL constructs had 
non-cleavable His6 tags, we performed the endo F1 digest with a very small amount of 
glycosidase (1:50 molar ratio of endo F1 to LCATFL) that we believed would not affect 
our downstream assays or crystallization experiments. As can be seen from Fig. 25, 
endo F1 completely digests LCATFL after 15 h incubation at 4 °C. The remaining 
heterogeneity of LCAT is probably due to some additional modification, such as O-
glycosylation. We attempted to separate different glycosylation species of LCAT using 
 
Figure 24. LCAT and LPLA2 expressed in 
stably transfected HEK 293S GnTi- cells 
before and after endo F1 treatment. (a) 
Coomassie stained gel. (b) The Western 
blot stained with anti-LPLA2 antibodies. (c) 
The Western blot stained with anti-LCAT 
antibodies. 
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chromatography on Phenyl Sepharose, 
however, LCATFL eluted as a single peak 
(data not shown). We also tried to use gel 
filtration in an attempt to separate different 
species by their size, but LCAT appeared to 
interact with the Superdex resin. Thus, we 
proceeded with crystallization experiments 
without further purification. 
 Melting temperatures of apo- and 
IDFP-bound LCATFL expressed in HEK 293F cells and HEK 293S GnTI- cells after endo 
F1 digest were nearly identical (data not shown) indicating that the enzyme is functional, 
thus, and if crystallized, would most likely represent a biologically relevant state.  
 
 
Figure 25 Large-scale LCATFL prep 
before and after endo F1 treatment. 
Coomassie-stained denaturing SDS-
PAGE. 
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2.3.3 Expression of under glycosylated LCAT species using 
glycosylation inhibitors  
In an attempt to produce underglycosylated LCAT species that would be 
amenable to endoglycosidase action we also tried using the inhibitors of the N-linked 
glycan maturation pathway. First, we chose to use kifunensine (KIF), an inhibitor of α-
mannosidase I. Proteins expressed in HEK 293T cells in the presence of this inhibitor 
exhibit oligomannose carbohydrate types, similar to those of the HEK 293S GnTI- cell 
line (V. T. Chang et al., 2007). We added KIF to the suspension cultures at the time of 
their transfection with pcDNA4-LCATFL plasmid. Cell media was harvested 4 d later and 
the protein was purified using methods described above for LCATFL. The Coomassie –
stained gel of purified LCATFL from cultures grown in the presence of 100 and 250 ng/ml 
of KIF is shown on Fig. 26. Compared to LCATFL expressed in HEK 293F cells without 
the inhibitor, the glycosylation of KIF-LCATFL appears to be different, however no less 
diffuse or heterogeneous. Low yields of this protein (less then 100 µg/L) and resistance 
to endo F1 led us to pursue other strategies.  
Next, we tried the α-
mannosidase II inhibitor, 
swainsonine (SWA). SWA 
inhibits the step of glycan 
processing, after the one 
blocked by kifunensine, and the 
carbohydrate, produced in the 
presence of SWA are hybrid-
types (V. T. Chang et al., 2007). 
Fig. 27 shows a representative 
gel of purified LCAT21-397 
expressed in the presence of 
different amounts of SWA and treated with endo F1 or endo Hf glycosidases. Test 
expression was also done with LCATFL and LCAT1-397 and the results completely mimic 
those of LCAT21-397 (data not shown). The most striking difference between LCAT 
 
Figure 26. LCATFL expressed in the presence if 
kifunensine (KIF) is resistant to endo F1. Lane1-  
glycosylated LCAT expressed in the absence of 
KIF. 
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produced in HEK 293F cells in the presence of KIF and SWA was the amount of 
expressed protein. While KIF treatment resulted in hardly any protein, glycosylation-
processing inhibition by SWA led to almost the same amount of protein as the “no 
inhibitor” sample.  Treatment with 14 µM SWA resulted in more homogenous LCAT21-397 
band compare to the “no SWA” sample (Fig. 27). Furthermore, SWA-LCAT21-397 could 
be almost completely deglycosylated with endo Hf, resulting in a single band at 43 kDa. 
Increasing SWA concentration in the cell culture media had no additional effect on the 
band homogeneity or its digestion by endo Hf. Interestingly, SWA-LCAT21-397 was 
resistant to endo F1. One significant difference between endo F1 and endo Hf is their 
ability to hydrolyze core-fucosylated glycans: endo Hf is about 50-fold faster than endo 
F1 (Sigma-Aldrich Co. LLC, 2008). Thus, LCAT expressed in the presence of SWA, 
likely, contains significant amount of fucosylated carbohydrates. LCAT21-397 could be 
further separated from endo Hf by gel filtration, as it no longer interacted with the resin 
and eluted as a single tight peak (data not shown). 
Thus, LCAT expression in HEK 293F cells in the presence of SWA seems very 
promising for producing pure homogenous protein in sufficient quantities for future 
crystallization trials. However, this protein is yet to be tested in activity and stability 
assays.  
 
 
Figure 27. LCAT21-397 expressed in HEK 293F cells in the absence and presence 
of swainsonine (SWA) before and after deglycosylation with endo F1 or endo Hf. 
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 Chapter 3. Crystallization and structure determination of 
LPLA2 and LCAT  
3.1 Crystallization of LPLA2 expressed in HEK 293T cells 
First, we crystallized the highly glycosylated LPLA2 purified from HEK 293T cells 
produced by Proteos, Inc. Rhombohedral crystals grew in 100 mM Na citrate pH 3.5-4, 
20% PEG 3350, and 100 mM NaCl to 300x300x30 µm (Fig. 28a). To confirm that 
crystals indeed contained LPLA2, we transferred ten crystals into the harvesting 
solution (20 mM HEPES pH7.5, 250 mM NaCl, 
100 mM Na citrate pH 4 and 20% PEG 3350), 
washed them three additional times with the 
same buffer to remove non-crystalline LPLA2, 
and then resuspended the crystals in SDS-
PAGE loading buffer and separated on the gel. 
After transfer to nitrocellulose e membrane the 
Western blot was stained with anti-LPLA2 
antibodies (Fig. 28b). In addition to testing the 
identity of the crystallized protein, we also 
wanted to identify whether or not we 
crystallized a small homogeneous fraction of 
the heterogeneously glycosylated LPLA2.  
However, the mobility and heterogeneity of 
crystallized LPLA2 was identical to that of the 
sample purified from HEK 293T cells (Fig. 
28b).  
 
Figure 28. Crystals of glycosylated 
LPLA2 expressed in HEK 293T 
cells. (a) LPLA2 crystals. Inset 
shows the crystal in polarized light. 
(b) The Western blot of purified 
LPLA2 and crystals harvested from 
the cryo loops after data collection. 
Lane 2 contains the same sample 
as in lane 1 diluted 5 times. 
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For cryoprotection we soaked the 
crystals in harvesting solution containing 
20% glycerol for 5-10 min. Data was 
collected at LS-CAT and GM/CA at 
Argonne Photon Source (statistics 
shown in a Table 2 is for GM/CA data 
collection) from crystals frozen in nylon 
cryoloops (Hampton).  Representative 
diffraction images at 0° and 90° φ we 
show in Fig. 29. The crystals diffracted 
to 3.4 Å spacings. However, as can be 
seen directly from the images, the 
diffraction was very anisotropic and 
maxima did not extended past 8 Å in 
one of the dimensions, which resulted in 
lower completeness overall and in 
highest resolution shell (89% and 90%, 
respectively). In addition, the crystals 
exhibited very high mosaicity (3°) 
reflecting overall disorder in the crystal 
Table 2. Data collection and refinement 
statistics for glycosylated LPLA2 
 apo LPLA2 (HEK293T) 
Data collection  
Beamline GM/CA  
23 ID-D 
Space group P 2 21 21 
Cell dimensions    
    a, b, c (Å) 72.4 125.3 140.2 
    α, β, γ  (°)  90 90 90 
Resolution (Å) 30 – 3.4 
(3.46 – 3.40) 
Rmerge 0.140 (0.590) 
I/σI 8.6 (1.5) 
Completeness (%) 89.0 (89.6) 
Redundancy 3.2 (3.1) 
  
Refinement  
Resolution (Å) 93.42 – 3.4 
(3.49 – 3.40) 
No. reflections 15210 (1039) 
Rwork/ Rfree 0.306/0.322 
No. atoms  
    Protein 6270 
    Ligand/ion 0 
    Water 0 
B-factors  
    Protein 123.3 
    Ligand/ion  
    Water  
R.m.s deviations  
    Bond lengths (Å)  0.023 
    Bond angles (º) 1.71 
Ramachandran 
favored (%) 89 
Ramachandran 
outliers (%) 2.4 
Each structure was solved using a single crystal. 
*Highest resolution shell is shown in parentheses 
parentheses parentheses.  
 
Figure 29. Diffraction images of HEK 293T LPLA2 crystals at 0° and 90° φ angle. 
Arrows indicate the highest resolution shell. 
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packing, which we attributed to either the highly complex heterogeneous glycosylation 
state of LPLA2 expressed in HEK 293T cells and/or overall flexibility of the protein. 
To reduce flexibility we stabilized LPLA2 with the covalent inhibitor MAFP, which 
increases LPLA2 melting temperature by 12 °C (Section 2.2). We tested LPLA2 
stabilization by MAFP at different pH and salt concentrations. MAFP stabilized LPLA2 at 
a wide range of pH from 4.5 to 9.5 and at both 130 mM NaCl (Fig. 30) and 500 mM 
NaCl (data not shown). Interestingly, whereas the LPLA2 melting temperature changes 
by only by 3.5 ° from pH 4.5 to pH 9.5, the LPLA2·MAFP complex melting temperature 
was bell-shaped, likely corresponding to the pH optimum of the catalytic triad, which 
depends on the protonation state of the catalytic histidine. This pH optimum is, however, 
different from the pH optimum of LPLA2 transacylase activity when using liposome-
based substrate (pH 4.5) (Abe & Shayman, 1998). Most likely, LPLA2 activity on 
liposomes requires low pH for electrostatic interactions between LPLA2 and the lipid 
surface. Crystals of LPLA2·MAFP were grown under the same conditions as Apo 
LPLA2, but they diffracted to the same resolution limits and their space group was 
identical. No improvement in diffraction quality was observed. 
We also crystallized LPLA2 expressed in HEK 293T cells after sialidase 
treatment (Section 2.1.2). However, 
these crystals were identical to 
crystals of fully glycosylated LPLA2 
(data not shown). 
Due to low resolution and high 
mosaicity of this LPLA2 crystal form 
we did not attempt experimental 
phasing and instead focused on 
getting new LPLA2 crystal forms using 
protein purified from the HEK 293S 
GnTI- cell line.    
 
Figure 30. Melting temperatures of Apo 
and MAFP-bound HEK 293T LPLA2 at 
different pH values.  
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3.2 Crystallization and structure determination of LPLA2 purified 
from HEK 293S GnTI- cells  
As described in Section 2.2, the activity and melting temperature of LPLA2 
expressed and purified from HEK 293S GnTI- cells and digested with endoglycosidase 
F1 (LPLA2F1) is similar to that of heavily glycosylated LPLA2 from HEK 293T cells. 
LPLA2F1 was crystallized by vapor diffusion in hanging drops over reservoirs containing 
100 mM HEPES pH 7.5, 3.5% PEG 8000, 28% MPD, and 300 mM ammonium 
phosphate. If crystals did not appear 
after 5 d, they were streak seeded 
using smaller LPLA2 crystals obtained 
at higher MPD and PEG 
concentrations. Due to the high MPD 
concentration, additional 
cryoprotection was unnecessary. 
LPLA2F1 crystals had P1 symmetry 
and diffracted to 1.83 Å spacings 
(Tables 3 and 4). To collect a high 
quality dataset with a low symmetry 
space group we employed the 5 µm 
mini-beam and vector data collection 
at GM/CA at APS. For this, the 
elongated plate-like crystal was 
oriented in the beam in such a way 
that φ angle rotation would be aligned 
along its longest axis. Then the best 
diffracting region was found using the 
rastering technique at GM/CA at APS. 
The 160 µM vector within the best 
diffracting zone, running in parallel to 
the rotation axis, was “split” into 16 
Table 3. Data collection and refinement 
statistics for LPLA2 expressed in HEK 293S 
GnTi- cells  
 apo LPLA2 SeMet LPLA2 
Data collection   
Beamline GM/CA  
23 ID-D 
GM/CA  
23 ID-D 
Space group P 1 P 21 
Cell dimensions     
    a, b, c (Å) 62.8 91.2 100.3 91.2 114.3 
100.4 
    α, β, γ  (°)  78.1 88.5 88.5 90 102 90 
Wavelength (Å) 0.97937 0.97937 
Resolution (Å) 30 –1.83 
(1.86 – 1.83)* 
29.7 – 2.79 
(2.94 – 2.79)* 
Rmerge 0.095 (0.631) 0.161 (0.529) 
I/σI 17.9 (2.2) 13.0 (5.2) 
Completeness (%) 97.8 (96.4) 99.2 (95.4) 
Redundancy 4.0 (3.9) 15.2 (14.5) 
   
Refinement   
Resolution (Å) 30 – 1.84 
(1.89 - 1.84) 
 
No. reflections 174208 (11119)  
Rwork/ Rfree 0.157/0.175  
No. atoms   
    Protein 12493  
    Ligand/ion 492  
    Water 1023  
B-factors   
    Protein 18.9  
    Ligand/ion 37.8  
    Water 36.6  
R.m.s deviations   
    Bond lengths(Å) 0.016  
    Bond angles (˚) 1.39  
Ramachandran 
favored (%) 
98  
Ramachandran 
outliers (%) 
0  
Each structure was solved using a single crystal.  
*Highest resolution shell is shown in parentheses.  
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spots, 10 µM apart. Each spot was used to collect 23 degrees of data (1° oscillation) for 
the full 360 ° total dataset. Data was processed using HKL2000 software package 
(Otwinowski & Minor, 1997). 
 
First we attempted to solve the structure by molecular replacement using 
PHASER (McCoy et al., 2007) and LPLA2 models built by the Robetta (Kim, Chivian, & 
Baker, 2004), I-Tasser (Y. Zhang, 2008)  or RaptorX (Peng & Xu, 2011)  servers. 
However, PHASER yielded no solution, most probably due to the low sequence identity 
of the proteins used to create initial LPLA2 models (16-19%). Next we turned to 
experimental phasing and attempted to soak heavy atoms into existing LPLA2 crystals. 
Table 4. Scaling statistics for LPLA2F1 crystals. 
Shell limit (Å) 
Average I Average error 
Normalized 
Chi2 
Linear R-
factor Lower Upper 
30 4.96 4975.8 124.7 2.536 0.058 
4.96 3.94 7135 176.6 2.313 0.053 
3.94 3.44 4710.3 138.2 1.906 0.058 
3.44 3.13 2953.4 107.7 1.617 0.067 
3.13 2.9 1745.2 83.2 1.38 0.082 
2.9 2.73 1182.5 71.4 1.237 0.1 
2.73 2.6 993.8 69.2 1.187 0.113 
2.6 2.48 778.3 65.3 1.091 0.132 
2.48 2.39 674.2 64.2 1.057 0.148 
2.39 2.31 599.2 64.2 1.012 0.165 
2.31 2.23 522.4 64.1 0.999 0.189 
2.23 2.17 456.7 64 0.96 0.212 
2.17 2.11 395.7 64 0.903 0.238 
2.11 2.06 363.9 65.3 0.902 0.266 
2.06 2.01 315 65.5 0.873 0.305 
2.01 1.97 265 65.5 0.79 0.347 
1.97 1.93 226.5 66 0.777 0.41 
1.93 1.9 199.9 66.5 0.772 0.472 
1.9 1.86 163.8 67.1 0.726 0.564 
1.86 1.83 146 67.6 0.686 0.631 
All reflections 1454.9 81.2 1.191 0.095 
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We tried soaks with 5 mM K2PtCl2, HgCl2, K2OsO4, KAu(CN)2; 2 mM Ethylmercuril 
thiosalicylate Na-salt (EMTS); 10 mM HoCl3 and UO2Cl2 for up to 3 d at 4 °C and rapid 
soaks which incubated LPLA2F1 crystals with 400 mM of CsCl or NaBr for 5 min. In 
most cases, incubation with heavy atoms resulted in a significant decrease of diffraction 
resolution (less then 5 Å) and overall quality (increased spot streakiness and mosaicity). 
However, crystals soaked with the uranium-containing compound diffracted to 2.2 Å. 
We collected data at 0.99987 Å (U f’’= 6.87), processed it the same way as for the 
LPLA2F1 data. However, no peaks were observed in the anomalous difference 
Patterson maps. Due to nonisomorphism (different unit cell) within the LPLA2F1 crystals 
without soaking, we were unable to search for the difference Patterson map peaks. 
Proteins, labeled with selenomethionine (SeMet) can often be crystallized under 
conditions identical to nonlabeled protein. Selenium has 18 more electrons compare to 
sulfur, which makes it suitable for isomorphous diffraction experiments. In addition Se 
has a weak anomalous signal, which, if measured accurately, could be useful for single-
wavelength anomalous diffraction (SAD) experiments. Labeling with SeMet is commonly 
used for proteins expressed in bacterial systems. In such cases bacteria are simply 
grown in minimal media supplemented with all essential amino acids and SeMet instead 
of methionine. In these prokaryotic systems, SeMet could be toxic for bacteria and 
yields of labeled protein are often significantly lower than for unlabeled protein. There 
are even fewer examples for SeMet labeling in more complex eukaryotic systems, such 
as in insect or mammalian cell cultures, because the toxic effects of SeMet are, usually, 
even more detrimental there. 
We first attempted to label LPLA2 
expressed in transiently transfected HEK 
293S GnTI- cells, using a protocol modified 
from Barton et al. (Barton, Tzvetkova-
Robev, Erdjument-Bromage, Tempst, & 
Nikolov, 2006). For this we grew HEK 293S 
GnTI- cells in 35x150 mm dishes in DMEM 
high-glucose media, supplemented with 
10% FBS, 1 mM pyruvate, 2 mM L-
Figure 31. Deconvoluted 
electrospray spectra of SeMet-
LPLA2F1. Molecular weight of 
LPLA2 with all LPLA2 with all Met 
substituted to SeMet is 44265 Da. 
SeM - selenomethionine 
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glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin to 90% confluence. Then the 
media was exchanged for complete media, deficient in cystine and methionine (Gibco), 
supplemented with 30 mg/l of cystine and 63 mg/l of SeMet, and followed by a 
transfection with PCEP4-LPLA2 plasmid (1:2 DNA:PEI ratio). Media was harvested after 
3 d and processed as described above for LPLA2F1.The yield was 200 µg total from 
35x150 mm plates.  
To increase the yield of SeMet labeled LPLA2, we used our stably transfected 
HEK 293S GnTi- cell line (Section 2.3.2). Grown in seven plates in the presence of 200 
µg/ml zeocin in DMEM high-glucose 
media, supplemented with 10% FBS, 1 
mM pyruvate, 2 mM L-glutamine, 100 
U/ml penicillin, and 100 µg/ml 
streptomycin to 90-95% confluence. 
Then cultures were split into 38 plates 
without antibiotic and grown for 
additional 3 d to 100% confluence. 
Subsequently, the media was changed 
to complete medium, deficient in 
cystine and methionine (Gibco), 
supplemented with with 30 mg/l of 
cystine and 63 mg/l of SeMet, 
harvested after 3 d and purified 
according to the protocol for LPLA2F1. 
The yield was 1 mg of SeMet-LPLA2F1 
from 1l of media. 
SeMet incorporation was 
confirmed using electrospray mass 
spectrometry with positive ion 
detection of the intact protein, wherein 
four separate peaks corresponding to 
8, 7, 6, and 5 methionines of LPLA2 
 
Figure 32. SeMet substructure of SeMet-
LPLA2F1 crystals. (a) Cross-correlation 
(CC) between observed and calculated 
Bijvoet differences for all (CC all) and 
weak (CC weak) reflections. (b) Se 
substructure (spheres) within the LPLA2 
asymmetric unit (surface representation). 
Each LPLA2 monomer is colored 
separately. 
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being substituted with SeMet were observed (mature LPLA2 has eight methionines) 
(Fig. 31). From the relative peak heights, the total incorporation was estimated to be 70-
80%. SeMet-LPLA2F1 crystals grew under the same experimental conditions as 
LPLA2F1. 
For experimental phase determination, the SeMet-LPLA2F1 dataset was collected 
using a 5 µm mini-beam and vector data collection at GM/CA at APS. Each site was 
used for collecting 20 ° wedges (10 ° direct and 10 ° inverse beam) for a total of 36 
spots that were 8 µM apart. As selenium has a weak anomalous signal, we used XDS 
for more accurate diffraction spot integration. In contrast to HKL2000, XDS uses a 3D 
profile fitting radius (Kabsch, 2010) and is superior for non perfect streaky images of 
SeMet-LPLA2F1. The data was merged with SCALA in the CCP4 suite (Evans, 2006; 
Winn et al., 2011).The selenium substructure, consisting of 32 Se sites (4 LPLA2 
molecules per asymmetric unit with eight methionines in each), was identified using 
10000 trials in ShelxD (T. R. Schneider & Sheldrick, 2002) (Fig. 32a) and initial phases 
(figure of merit = 0.35) were determined by single anomalous diffraction in AutoSol as 
implemented in the Phenix software package (P. D. Adams et al., 2010; Terwilliger et 
al., 2009) (Fig. 32b). The initial atomic model was created with Phenix AutoBuild 
(Terwilliger et al., 2008). This preliminary SeMet-LPLA2 structure was used as a search 
model in molecular replacement using PHASER (McCoy et al., 2007) to solve the native 
LPLA2F1 structure (Table 3 and Fig. 33) as these crystals were nonisomorphous with 
those of SeMet-LPLA2F1. Refinement was performed with alternating rounds of TLS and 
restrained refinement in REFMAC5 (Murshudov et al., 2011)  and model building in 
Coot (Emsley, Lohkamp, Scott, & Cowtan, 2010). During refinement, local NCS 
restraints were applied when appropriate. Structure validation was performed using the 
Molprobity server. 
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Figure 33. Ramachandran plot for LPLA2F1. 97.9% (1567/1600) of all residues were 
in favored (98%) regions. 100.0% (1600/1600) of all residues were in allowed 
(>99.8%) regions. 
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3.3 Structure determination of different LPLA2 crystal forms by 
molecular replacement 
To get more information about the LPLA2 catalytic mechanism, we attempted to 
obtain the structure of LPLA2 bound to its substrates. We have tried soaking NAS, N-
acetyl-serine (resembles NAS head group), glycerol (acyl group acceptor at 
concentrations higher then 30% (Abe, Hiraoka, & Shayman, 2007b)),  1,2-dioctanoyl-PC  
(short chain PC analog), 1,2 heptanoyl-thio-PC (nonhydrolysable short chain PC 
analog), POPC and lysoPC by themselves and with detergents (2% n-dodecyl-beta-D-
maltoside or β-OG). However, no ligand electron density could be observed after 
structure solution and refinement.  
In addition, we have also explored co-crystallization of LPLA2F1 and its 
catalytically dead mutant, S165A, with DOPC-sulfatide liposomes (1.25 mM DOPC: 
0.13 mM sulfatide), as co-crystallization with micelles has been used previously to 
obtain a phospholipid-bound structure of pancreatic lipase (van Tilbeurgh et al., 1993). 
After mixing LPLA2 with liposomes we set up the sparse matrix JCSG+ and Classics 
Lite Suite screens (Qiagen). Crystals of LPLA2F1-S165A were grown using a condition 
from the Classics Lite Suite (Qiagen): 100 mM Na cacodylate pH 6.5, 10% PEG 8000, 
200 mM MgAc2 and cryoprotected in solution containing 100 mM Na cacodylate pH 6.5, 
50mM Na citrate pH 4.5, 20 mM HEPES pH 7.5, 10% PEG 8000, 200 mM MgAc2, and 
30% ethylene glycol. The crystal structure of S165A-LPLA2F1 was solved using 
molecular replacement method with LPLA2F1 as a search model. Although we were able 
to obtain a novel LPLA2 crystal form (Table 5), the lipase active site remained empty.  
Thus, we turned to nonspecific covalent phospholipase inhibitors, IDFP and 
MAFP. These inhibitors have been used previously to obtain the crystal structures of the 
human pancreatic lipase and dog gastric lipase in their active conformation (Egloff et al., 
1995; Roussel et al., 2002).  
Both IDFP and MAFP increase LPLA2 melting temperature when tested in the 
ThermoFluor assay (Fig. 34). The longer MAFP inhibitor changes LPLA2 melting 
temperature by 12 °C, while IDFP, whose acyl chain is eight carbon atoms shorter then 
that of MAFP, changes LPLA2 melting temperature only by 10 °C. This trend is 
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consistent with the low efficiency of LPLA2 hydrolysis for short acyl chain phospholipids, 
such as octanoyl-PC (data not shown). 
For cocrystallization experiments with IDFP 
and MAFP, LPLA2 was first covalently modified 
with IDFP or MAFP. For this, 50 µM 
fluorophosphonate inhibitors (Cayman chemical) 
in methyl acetate were incubated with 0.4 mg/ml 
LPLA2 for 1 h at room temperature, and then 
LPLA2 was concentrated to 10-13 mg/ml. Then we 
set up commercially available sparse matrix 
screens (QIAGEN and Hampton) and screened 
around previously optimized conditions for 
LPLA2F1 crystals. Sparse matrix screening yielded 
multiple hits that were not observed for apo 
LPLA2. In particular, a diamond-shaped LPLA2·MAFP crystal form crystallized using 
100 mM HEPES pH 7.5, 30% PEG MME 550, 50 mM MgCl2. Due to the high PEG MME 
concentration, these crystals did not require cryoprotection. The structure was solved in 
P 43212 space group by molecular replacement (Table 5). 
Crystals of LPLA2·IDFP and LPLA2·MAFP were also obtained in conditions 
similar to apo-LPLA2F1 crystals (100 mM HEPES pH 6.5, 3.5% PEG 8000, 28% MPD, 
and 300 mM ammonium phosphate). In addition, both inhibitors could also be soaked 
into crystalline LPLA2 using harvesting solution containing 1 mM IDFP or MAFP for 2 d, 
and then freezing the crystals on nylon loops in liquid N2. Cocrystallization and soaking 
with inhibitors resulted in the same LPLA2 conformation with identical ligand 
orientations. However, datasets from inhibitor soaks diffracted to slightly higher 
spacings (2.3 Å for P1 LPLA2·IDFP and 2.7 for P1 LPLA2·MAFP) and, thus, were used 
for future analysis  (Table 5). IDFP and MAFP were modeled into the active site using 
Coot and refinement was done in REFMAC5 using external restraints generated in 
JLigand (Lebedev et al., 2012).  
We were also able to solve the structures of glycosylated LPLA2 produced in 
HEK 293 GnTI- or HEK 293T cells (Tables 4 and 2) by molecular replacement using 
 
Figure 34. Increase of LPLA2 
melting temperature in the 
presence of covalent inhibitors 
IDFP and MAFP 
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LPLA2F1 as a search model. For the P 6222 crystals of high-mannose LPLA2, the 
protein was produced in HEK 293 GnTI- cells (without endo F1 treatment), conjugated 
with MAFP and crystallized in 100 mM citric acid pH 3, 0.8 M ammonium sulfate in a 
condition derived from the JCSG+ screen (Qiagen). Cryoprotection was achieved by 
harvesting solution containing 30% glycerol, 20 mM HEPES pH7.5, 150 mM NaCl, 100 
mM citric acid pH 3 and 0.8 M ammonium sulfate. Comparison and detailed analysis of 
LPLA2 crystal structures is given in Chapter 4. 
 
Table 5. Data collection and refinement statistics for crystal forms of LPLA2 
expressed in HEK 293S GnTi- cells  
 LPLA2·IDFP 
(+endoF1) 
LPLA2·MAFP 
(+endoF1) 
LPLA2 S165A 
(+endoF1) 
LPLA2·MAFP 
(+endoF1) 
LPLA2·MAFP  
Data collection      
Beamline LS-CAT  
21 ID-D 
LS-CAT  
21 ID-D 
GM/CA  
23 ID-D 
GM/CA  
23 ID-D 
GM/CA  
23 ID-D 
Space group P 1 P 1 F 41 3 2 P 43 21 2 P 62 2 2 
Cell dimensions        
    a, b, c (Å) 62.8 90.2 99.3 69.1 85.5 90.3 257 257 257 86.8 86.8 366 96.0 96.0 208.0 
    α, β, γ  (°)  100.9 91.1 
89.1 
88.9 70.9 79.7 90 90 90 90 90 90 90 90 120 
Resolution (Å) 30 – 2.30 
(2.34 – 2.30) 
30 – 2.70 
(2.75 – 2.70) 
30 – 3.00  
(3.05 – 3.00) 
30 – 2.85 
(2.90 – 2.85) 
30 – 2.70 
(2.75 – 2.70)* 
Rmerge 0.080  (0.508) 0.088 (0.394) 0.211 (0.911) 0.157 (0.753) 0.132 (0.771) 
I/σI 10.6 (1.5) 9.3 (1.8) 8.8 (1.9) 22.9 (3.5) 28.6 (3.7) 
Completeness (%) 98.2 (97.4) 98.1 (93.7) 98.1 (100) 99.9 (100) 99.9 (98.6) 
Redundancy 2.0 (2.0) 2.0 (1.9) 5.3 (5.3) 14.7 (14.8) 12.5 (12.1) 
      
Refinement      
Resolution (Å) 97.53 – 2.28  
(2.34 – 2.28) 
85.2 – 2.69 
(2.76 – 2.69) 
29.7 – 3.0  
(3.08 – 3.00) 
29.8 – 2.84 
(2.91 – 2.84) 
29.4 – 2.79 
(2.86 – 2.79) 
No. reflections 90291 (5699) 49231 (3274) 14088 (1012) 32375 (2252) 14002 (970) 
Rwork/ Rfree 0.178/0.206 0.189/0.222 0.189/0.226 0.197/0.223 0.244/0.308 
No. atoms      
    Protein 12470 12109 3048 6062 3002 
    Ligand/ion 538 373 56 84 0 
    Water 543 193 1 0 0 
B-factors      
    Protein 26.4 22.9 44.9 61 55.2 
    Ligand/ion 24.8 54.4 65.4 84.4  
    Water 50.6 24.9 2.7 -  
R.m.s deviations      
    Bond lengths(Å) 0.011 0.009 0.008 0.01 0.013 
    Bond angles (˚) 1.45 1.22 1.22 1.35 1.71 
Ramachandran 
favored (%) 
98 97 94 96 
93 
Ramachandran 
outliers (%) 
0 0 0.79 0.66 
2.4 
Each structure was solved using a single crystal.  
*Highest resolution shell is shown in parenthesis.  
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3.4 Determination of the low resolution LCAT structure 
We next attempted to determine the structure of LCAT. Unfortunately, we were 
unable to crystallize LCATFL or LCAT1-397 expressed in HEK 293F cells, but we could 
generate the crystals for LCAT21-397 (Fig. 35 
and Table 6 and 7) using 100 mM Na acetate 
pH 5.0, 13% isopropanol, and 200 mM CaCl2.  
Cryoprotection was achieved by adding dry 
glucose to a final concentration of 30% (w/v) in 
mother liquor, due to the volatility of 
isopropanol. To determine the LCAT21-397 
structure, the apo-LPLA2 model was truncated 
to the last common Cβ and used as a search 
model in PHASER. An LPLA2-based homology 
model, built using the UCSF Chimera package 
(Pettersen et al., 2004), was then 
superimposed onto the solution and used as 
the starting point for structure refinement. Four-
fold NCS restraints were applied during 
refinement with restrained and jelly body 
refinement in REFMAC (Table 6 and Fig. 36). 
Stunningly, these crystals contained 88% 
solvent, explaining their diffraction to low 
resolution (8.7 Å). However, the electron 
density maps were of excellent quality. 
 
Figure 35. LCAT21-397. (a) and (b) 
show the crystals of LCAT21-397 
photographed in white and 
polarized light, respectively. (c) 
High solvent content of LCAT 
crystals is due to large solvent 
channels. Shown are symmetry 
mates generated by PyMol within a 
50 Å radius. Four LCAT monomers 
are colored separately. 
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We have also performed extensive crystallization screening for LCAT expressed 
in the HEK 293S GnTi- cell line. We have attempted to crystallize it in its apo and IDFP 
–bound form, with and without detergents (DDM and β-octylglucoside). However, no hits 
were observed. This could be attributed to the heterogeneity of the sample (Section 
2.3.2).  
We have tried to reduce 
heterogeneity by partial protease 
digest with trypsin and clostripain. 
Although we were able to obtain a 
single species of LCAT (data not 
shown), its low molecular weight, 
determined by electrospray mass-
spectrometry (31122 Da), indicated 
that a significant portion of the 
protein was missing. Thus, we 
decided to not pursue this 
approach further. 
While we have not yet 
performed extensive screening of 
LCAT expressed in HEK 293F cells 
in the presence of swainsonine, we 
expect this protein form to be the 
most promising lead in future 
attempts to obtain LCAT crystals 
diffracting to a higher resolution. 
Table 6. Data collection and refinement 
statistics for LCAT21-397 
 LCAT21-397 
Data collection  
Beamline LS-CAT 21 ID-D 
Space group H3 
Cell dimensions    
    a, b, c (Å) 367 367 187 
 
    α, β, γ  (°)  90 90 120 
Resolution (Å) 30 – 8.70  
(8.85 – 8.70)* 
Rmerge 0.189 (0.529) 
I/σI 8.2 (1.55) 
Completeness (%) 98.8 (94.8) 
Redundancy 5.1 (4.8) 
  
Refinement  
Resolution (Å) 29.9-8.69 (8.90-8.69) 
No. reflections 6954 (332) 
Rwork/Rfree 0.152/0.195 
No. atoms  
    Protein 12224 
    Ligand/ion 332 
    Water 0 
B-factors  
    Protein 298.1 
    Ligand/ion 338.6 
    Water  
R.m.s deviations  
    Bond lengths (Å)  0.01 
    Bond angles (º) 1.7 
Ramachandran favored (%) 92 
Ramachandran outliers (%) 2 
Structure was solved using a single crystal. 
*Highest resolution shell is shown in parenthesis.  
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Table 7. Scaling statistics for LCAT21-397 crystals. 
Shell limit (Å) 
Average I Average error 
Normalized 
Chi2 
Linear R-
factor Lower Upper 
30	   20.8	   91.9	   4.9	   2.117	   0.093	  
20.8	   17.54	   55.6	   2.9	   2.106	   0.128	  
17.54	   15.68	   39.9	   2.5	   1.611	   0.142	  
15.68	   14.42	   31.9	   2.4	   1.382	   0.157	  
14.42	   13.49	   31.1	   2.5	   1.384	   0.17	  
13.49	   12.76	   29	   2.6	   1.406	   0.186	  
12.76	   12.16	   28.6	   2.7	   1.147	   0.175	  
12.16	   11.67	   30.2	   2.8	   1.313	   0.187	  
11.67	   11.24	   26	   2.8	   1.078	   0.192	  
11.24	   10.87	   23	   2.9	   1.029	   0.217	  
10.87	   10.55	   19.1	   2.9	   0.819	   0.228	  
10.55	   10.26	   15.2	   2.8	   0.655	   0.251	  
10.26	   10	   12.6	   2.9	   0.571	   0.274	  
10	   9.76	   11.2	   3	   0.536	   0.302	  
9.76	   9.55	   10.1	   3.1	   0.457	   0.311	  
9.55	   9.35	   8.7	   3	   0.441	   0.37	  
9.35	   9.17	   8.6	   3.1	   0.377	   0.345	  
9.17	   9	   7.4	   3.2	   0.367	   0.397	  
9	   8.85	   5.7	   3.1	   0.337	   0.499	  
8.85	   8.7	   5.1	   3.3	   0.281	   0.529	  
All reflections 24.7	   3	   0.972	   0.189	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Figure 36. Ramachandran plot for LCAT21-397. 92.0% (1391/1512) of all residues 
were in favored (98%) regions. 98.0% (1482/1512) of all residues were in allowed 
(>99.8%) regions. 
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 Chapter 4. Structural and functional analysis of LPLA2 
and LCAT 
4.1 Atomic Structure of LPLA2. 
The crystal structure of human LPLA2 (Fig. 37) was determined to 1.83 Å 
spacings using protein secreted from HEK293S GnTI- cells and deglycosylated with 
endoF1 (LPLA2F1) (Fig. 18a-d, Table 3). Experimental phases for the structure were 
obtained via single wavelength anomalous diffraction from crystals containing SeMet 
labeled protein (Table 3). LPLA2 bears several structural and functional similarities to 
Family I bacterial triacylglycerol lipases (Arpigny & Jaeger, 1999). First, it contains a 6-
stranded α/β hydrolase domain, lacking the first two strands of the canonical fold (Ollis 
et al., 1992). The catalytic triad of the domain is found at conserved topological 
positions in the fold, with Ser165 in a nucleophile elbow between β5 and αC, Asp327 in a 
loop before αE, and His359 in a loop following β8 (Fig. 37b). Second, the enzyme has a 
“cap” domain formed by the β6-β7 and β7-αE loops of the α/β hydrolase domain. In the 
bacterial lipases, the cap domain contributes to the ligand binding site and typically 
features a flexible lid element that shields the hydrophobic active site from solvent in the 
soluble form of the enzyme (Nardini & Dijkstra, 1999; Schrag et al., 1997). The LPLA2 
cap domain is unrelated in fold, but contains two helices (a3 and a5) that are structurally 
analogous to two key helices found in bacterial lipase cap domains (α4 and α6), which 
help to form the binding site for the scissile acyl chain of the triacylglycerol substrate 
(Fig. 38). 
Unique to LPLA2, however, is a domain inserted in the loop between β3 and αA´ 
that contains the sole disulfide bond of the protein and a rare non-proline cis-peptide 
bond between Trp43 and Leu44 that allows both of their hydrophobic side chains to 
project into the active site. Relative to Family I bacterial lipases, the domain occupies a 
similar topological position as the lid element (α5) in its open configuration (Fig. 38b-c). 
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Figure 37. Architecture of LPLA2. (a) The α/β hydrolase (gold with orange strands), 
membrane binding (magenta), and cap (purple) domains associate to form a large 
concave active site cleft. Catalytic triad residues are drawn with green carbons. N-
acetylglucosamine sugars (grey spheres) are observed at Asn66, Asn240, Asn256, 
and Asn365. The sole disulfide bond between Cys32 and Cys56 is drawn with yellow 
sulfur atoms. Side chains shown to play a role in membrane binding are shown as 
magenta sticks. Inset displays a close up view of the catalytic triad region. (b) LPLA2 
topology. Because LPLA2 lacks the first two β strands of the canonical fold, the first 
strand of the α/β hydrolase domain is denoted as β3 (Schrag et al., 1997). (c) Cross-
eyed stereo image of the LPLA2 Cα trace. Domain coloring is the same as in (a), and 
the observed amino and carboxyl terminal residues are labeled N and C, 
respectively. 
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The domain forms extensive interactions with the cap domain, in particular via its 
extended b4-b5 hairpin loop (residues 61-75), which buries 1055 Å2 (calculated using 
PISA software (Krissinel & Henrick, 2007)) of accessible surface area. Because this 
domain features a conserved hydrophobic surface that faces away from the active site 
(Fig. 37a) and, as shown later, mediates LPLA2 interactions with membranes, it is 
henceforth referred to as the membrane binding domain. 
The three domains of LPLA2 assemble to form a large concave surface 
containing the catalytic triad at the bottom, with all three domains providing many 
surface exposed hydrophobic residues that would favor the binding of lipid reactants. 
Compared to other lipases, which are known to have both active (open) and inactive 
 
Figure 38. Structural comparison of Family I triacylglycerol lipases with LPLA2. These 
enzymes have a similar α/β hydrolase core and have cap domains containing a 
topologically and structurally similar motif of two helices (colored cyan) separated by a 
loop with an intervening helix (dark grey). In the bacterial lipases, this helix (α5) 
functions both as an active site lid in the closed state and membrane binding element in 
the open state. (a) Closed conformation of triacylglycerol lipase from Pseudomonas 
glumae (PDB entry 1TAH). (b) Pseudomonas cepacia lipase (PDB entry 2LIP) in an 
open conformation. Potential membrane binding residues are shown as spheres. (c) In 
comparison, LPLA2 seems to exhibit an open conformation, and its membrane binding 
domain occupies a similar topological location with respect to the active site as the α5 
helix in panel B. Hydrophobic residues shown to be involved in membrane binding are 
shown as spheres. The lid loop and subsequent a4 helix of the cap domain (dark gray) is 
topologically equivalent to α5 in panels A and B. 
 
 74 
(closed) conformations (Nardini & Dijkstra, 1999; van Tilbeurgh et al., 1993), access to 
the LPLA2 active site seems unimpeded except for a flexible ten residue loop between 
the a3 and a4 helices of the cap domain, topologically equivalent to the larger lid 
elements found in Family I bacterial lipases (Fig. 38). Because this element (the “lid 
loop”) is not highly conserved in sequence between LPLA2 and LCAT enzymes, it could 
play a role in determining their selectivity for NAS and cholesterol, respectively (see 
below), as acyl acceptor substrates. 
 
4.2 Phospholipid Substrate Binding Site of LPLA2.  
Phospholipids or phospholipid analogs have not yet been co-crystallized with 
either wild-type or catalytically inactive LPLA2-S165A. However, structures of LPLA2 
bound to fluorophosphonate inhibitors are expected to mimic the tetrahedral acyl 
intermediate transition state of the reaction (Abe et al., 2010) (Table 5). The structures 
of LPLA2 bound to IDFP (2.3Å spacings) and MAFP (2.7 Å spacings) have a root-
mean-square deviation (RMSD) of 0.17 for 376 equivalent Cα atoms compared to apo 
LPLA2, and thus induce no major structural rearrangements despite increasing the 
melting point (Tm) by 10-12 ˚C (Fig. 34). Omit map density reveals strong electron 
density for the MAFP and IDFP head groups, wherein the phosphonate group is 
covalently bound to Ser165 and occupies the oxyanion hole formed by the backbone 
amides of Asp13 and Met166 (Fig. 39 and 40). The density becomes progressively 
weaker after the C3 carbon of their alkyl chains. Heterogeneity in the position of the 
aliphatic tail of IDFP suggests that there are two distinct hydrophobic tracks (A and B) 
leading away from the catalytic triad (Fig. 39a and c) that likely correspond to the 
binding sites for the sn-1 and sn-2 acyl tails of the phospholipid substrate. Track A, 
which modeling indicates could readily accommodate at least 18 carbons, is curved and 
follows a hydrophobic band of residues on helices a3 and a5 in the cap domain, ending 
in a hydrophobic cleft formed by the side chains of Trp43, Trp57, Ile61, and Trp130 (Fig. 
39a and b). An unusual feature of this track is the side chain of Asp13, which in bacterial 
lipases is conserved as leucine or methionine. The acyl chain occupying track A would 
therefore need to skirt around this residue to avoid unfavorable contacts, although in the 
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low pH of the lysosome this residue should be at least partially protonated. Notably, 
Asp13 is conserved as Cys31 in LCAT, a position well established as being important 
for cholesterol binding and modulation of LCAT catalytic activity (Boone et al., 2012; 
 
Figure 39. Complexes with fluorophosphonate inhibitors help define the catalytic 
cycle of LPLA2. (a) IDFP (cyan sticks) occupying track A. Wire cages in panels a-d 
correspond to 2.5 σ |Fo|-|Fc| omit maps. (b) Backbone amides of Asp13 and Met166 
form the oxyanion hole of LPLA2 and coordinate the phosphonate group. (c) IDFP 
in chains A, B and D of the LPLA2·IDFP structure occupies track B. (d) Regardless 
of the track, the phosphonate of the IDFP head group forms hydrogen bonds 
(dashed blue lines) with the backbone amides of Asp13 and Met166 comprising the 
oxyanion hole. Residues defining tracks A and B are shown as sticks with carbons 
colored according to their domain assignment as in Figure 37. 
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Francone & Fielding, 1991a; Jauhiainen et al., 1988). Interestingly, the pKa of cysteine 
is such that Cys31 will likewise be partially deprotonated in its native environment in 
human plasma at pH 7.4.  
Track B is much more solvent 
accessible and linear than track A, 
starting adjacent to the oxyanion hole 
between the side chains of Leu14 (which 
contributes to both tracks) and Tyr104 in 
the catalytic domain, then extending along 
the surface of the membrane binding 
domain, including residues Trp43 and 
Leu44, within a channel formed between 
the lid loop of the cap domain, the αA´-αA 
loop of the catalytic domain, and the a1 
helix of the membrane binding domain 
(Fig. 39c and d). Consistently, MAFP, 
which has a long arachidonyl group (20 
carbon atoms), is only found occupying track B (Fig. 40) 
 
 
Figure 40. MAFP occupies track B of 
LPLA2. Residues defining track B are 
shown as sticks with carbons colored 
according to their domain assignment 
as in Figure 37.  
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4.3  Catalytic Cycle.  
Although LPLA2 exhibits some structural homology with bacterial lipases, their 
substrates are fundamentally different in that LPLA2 and LCAT hydrolyze 
glycerophospholipids, which contain polar, charged head groups. Accordingly, there are 
modifications in conserved elements of the catalytic and cap domains of LPLA2 that can 
accommodate this difference. Lys202 in the a3 helix and Thr329 in the catalytic domain 
are invariant in LPLA2 and LCAT, but are conserved as hydrophobic residues in 
bacterial triacylglycerol lipases. Modeling indicates that they could form specific 
hydrogen bonds with the phosphate in the phospholipid head group (Fig. 41). The 
guanidinium of Arg214 in the lid loop is also in close proximity, although this residue is 
substituted with glycine in LCAT. The K202A, N213Q/R214A, and T329A mutations all 
retained full ability to hydrolyze the soluble substrate p-nitrophenylbutyrate (pNPB), 
indicating proper fold (Fig. 42a), but only K202A and T329A were deficient in catalyzing 
acyl transfer to NAS (Fig. 42b), indicating that Lys202 and Thr329, but not Arg214, are 
important for phospholipid binding. These results allowed creation of a docking model 
for a typical preferred phosphatidylcholine (PC) substrate with a saturated acyl group in 
the sn-1 position (palmitate), and an unsaturated, longer fatty acid (oleic acid) in the sn-
 
Figure 41. Models of the LPLA2 catalytic cycle. (a) Model of POPC (spheres) bound in 
the active site such that its sn-2 chain occupies track A, and sn-1 track B. The head 
group (light grey spheres) is coordinated by Lys202, Asp211, and Thr329. (b) After 
dissociation of the lysophosphatidylcholine product, the acyl intermediate remains in 
track A, which would allow His359 to deprotonate the incoming alcohol nucleophile. (c) 
Model of NAS (blue spheres, cyan acetyl group) bound in track B. 
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2 position (Fig. 41a) (Abe et al., 2006). In support of the model, the A and B tracks 
extending from the catalytic triad adopt trajectories that loosely match the 
physicochemical propensities of each acyl chain (i.e. kinked vs. linear), which may help 
explain the preference of LPLA2 for unsaturated lipids in the sn-2 position. Based on 
constraints of the phosphate interacting with Lys202 and Thr329, the positively charged 
amine of the choline head group would be close enough to form favorable electrostatic 
interactions with the side chain of Asp211 in the lid loop, an invariant residue in both 
LPLA2 and LCAT. Although LPLA2 has relatively broad head group selectivity (Abe & 
Shayman, 2009), LCAT is fairly specific for PC (Pownall et al., 1985) and the analogous 
residue (Asp227) may be important for this property. 
The side chain of Asp13 is also expected to be involved in substrate binding, 
perhaps by helping to dictate the course of acyl chains in track A. Accordingly, the D13A 
mutation decreased both soluble substrate pNPB hydrolysis and acyl transfer (Fig. 42a, 
b), suggesting that truncation of the side chain at this position disrupts the formation of 
favorable van der Waals contacts with the butyric group of the substrate. 
The above data suggest the following steps for phospholipid binding, acyl 
intermediate formation, lysophospholipid release, and transfer to acyl acceptor. The 
phospholipid acyl chain that binds in track A corresponds to the scissile chain given the 
homology of this site to those of bacterial lipases and the fact that the catalytic triad 
histidine is situated such that it can only protonate the lysophospholipid leaving group if 
it resides in track B (Fig. 41a). However, because LPLA2 has both phospholipase A2 
and A1 activity, whether the sn-1 or sn-2 chain binds in track A also depends on its 
physicochemical properties (size and curvature). Indeed, LPLA2 prefers to transfer oleic  
(C18:1) and linoleic (C18:2) fatty acids (Abe et al., 2006) perhaps because their length 
and unsaturation enables them to pack more efficiently in track A. After dissociation of 
the lysophospholipid product (Fig. 41b) the more accessible track B is left open for 
binding water (leading to lipase activity) or lipophilic alcohols (leading to acyl transferase 
activity) (Fig. 41c). A model of NAS docked into track B of the LPLA2 active site 
potentially explains the preference of the enzyme for lipophilic alcohols with a short side 
chain, such as C2 ceramide (Abe, Hiraoka, & Shayman, 2007b), because longer chains 
could collide with the acyl-intermediate bound in track A (Fig. 41c). The residues that 
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coordinate the phosphate of the PC head group may also form specific hydrogen bonds 
with the N-acetyl group of NAS.  
 
 
 
Figure 42. Enzymatic activity and membrane binding of LPLA2. (a) Hydrolysis of the 
soluble substrate pNPB at pH 7.5. All mutations except D13A were not significantly 
different from wild-type (wt). (b) Transacylase assay using NAS-DOPC-sulfatide 
liposomes. Transacylase assays were performed by V. Hinkovska-Galcheva. (c) 
LPLA2 co-sedimentation with DOPC-sulfatide liposomes. Error bars represent the 
standard deviation of three independent experiments. ** 0.001<p<0.01, ***p<0.001. 
na, not assayed due to poor protein expression. 
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4.4  Conformational Flexibility of LPLA2.  
Conformational flexibility is often an important structural property of lipases, as 
interaction with a lipid bilayer is often thought to induce a conformational change that 
opens the active site (Verger, 1997). Among the eight unique crystal forms for apo- and 
inhibitor-bound LPLA2 reported here (Tables 2-4), the most conformationally variable 
element is the lid loop (residues 210-220) (Fig. 43a). The αA´-αA loop (residues 96-
102) and the a1 helix of the membrane binding domain are also among the most flexible 
elements, consistent with their temperature factors in the free enzyme structure (Fig. 
43b). Interestingly, all three of these elements contribute residues to track B, suggesting 
that their structural plasticity allows for the binding of distinct ligands in this track, as is 
required by the catalytic cycle. Sequence alignment of these regions in LPLA2 and 
LCAT reveals high conservation within each enzyme family, but less so between LPLA2 
and LCAT (Fig. 43c), and thus these loops could play a role in dictating acyl acceptor 
selectivity. However, despite similarities to Family I bacterial lipases (Fig. 38), there is 
as of yet no evidence of a large conformational change that would transition LPLA2 
from a closed to an open state upon membrane binding. 
